PKCZ
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| O00571 | S606 | Sugiyama | DDX3X DBX DDX3 | GRSKssRFsGGFGARDYRQssGAssssFsssRAsSsRSGGG |
| O14920 | S177 | SIGNOR|PSP | IKBKB IKKB | EQRLIHKIIDLGYAKELDQGsLCTsFVGTLQyLAPELLEQQ |
| O14920 | S181 | SIGNOR|PSP | IKBKB IKKB | IHKIIDLGYAKELDQGsLCTsFVGTLQyLAPELLEQQKyTV |
| O14974 | S910 | Sugiyama | PPP1R12A MBS MYPT1 | yETssTsAGDRyDsLLGRsGsysYLEERKPYSSRLEKDDST |
| O15371 | T49 | Sugiyama | EIF3D EIF3S7 | PyQPFsKGDRLGKVADWtGAtyQDKRYTNKYSSQFGGGSQY |
| O43175 | S55 | PSP | PHGDH PGDH3 | NLSKEELIAELQDCEGLIVRsAtKVTADVINAAEKLQVVGR |
| O43175 | T57 | PSP | PHGDH PGDH3 | SKEELIAELQDCEGLIVRsAtKVTADVINAAEKLQVVGRAG |
| O43175 | T78 | PSP | PHGDH PGDH3 | KVTADVINAAEKLQVVGRAGtGVDNVDLEAAtRKGILVMNT |
| O43315 | S11 | SIGNOR|ELM|PSP | AQP9 SSC1 | __________MQPEGAEKGKsFKQRLVLKSSLAKETLSEFL |
| O43315 | S222 | ELM|PSP | AQP9 SSC1 | VIASSLGLNSGCAMNPARDLsPRLFTALAGWGFEVFRAGNN |
| O43852 | S44 | Sugiyama | CALU | KKDRVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQL |
| O43852 | Y47 | Sugiyama | CALU | RVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQLtPE |
| O60814 | S39 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O60841 | S196 | Sugiyama | EIF5B IF2 KIAA0741 | ERsRINssGEsGDEsDEFLQsRKGQKKNQKNKPGPNIEsGN |
| O95678 | S162 | Sugiyama | KRT75 K6HF KB18 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| O95863 | S249 | SIGNOR|PSP | SNAI1 SNAH | THsDVKKYQCQACARTFsRMsLLHKHQESGCSGCPR_____ |
| O96013 | S99 | PSP | PAK4 KIAA1142 | DGALTLLLDEFENMSVTRsNsLRRDsPPPPARARQENGMPE |
| P00338 | S167 | Sugiyama | LDHA PIG19 | AWKISGFPKNRVIGsGCNLDsARFRyLMGERLGVHPLSCHG |
| P02538 | S176 | Sugiyama | KRT6A K6A KRT6D | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWT |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04259 | S176 | Sugiyama | KRT6B K6B KRTL1 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | T237 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | VGKVIPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDD |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05023 | S16 | SIGNOR | ATP1A1 | _____MGKGVGRDKyEPAAVsEQGDKKGKKGKKDRDMDELK |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05455 | S325 | Sugiyama | SSB | VLEGEVEKEALKKIIEDQQEsLNKWKSKGRRFKGKGKGNKA |
| P05787 | S104 | Sugiyama | KRT8 CYK8 | IQAVRTQEKEQIKTLNNKFAsFIDKVRFLEQQNKMLETKWS |
| P06733 | S27 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | HAREIFDsRGNPtVEVDLFtsKGLFRAAVPsGAstGIyEAL |
| P06899 | S39 | Sugiyama | H2BC11 H2BFR HIST1H2BJ | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISSKA |
| P07195 | S168 | Sugiyama | LDHB | TWKLSGLPKHRVIGsGCNLDsARFRyLMAEKLGIHPSSCHG |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07737 | T65 | Sugiyama | PFN1 | PAEVGVLVGKDRssFyVNGLtLGGQKCsVIRDsLLQDGEFs |
| P07814 | S335 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PIEKNLQMWEEMKKGsQFGQsCCLRAKIDMSSNNGCMRDPt |
| P07864 | S167 | Sugiyama | LDHC LDH3 LDHX | VWKISGLPVTRVIGsGCNLDsARFRYLIGEKLGVHPTSCHG |
| P07900 | S53 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDsG |
| P07900 | S63 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IFLRELIsNssDALDKIRyEsLtDPsKLDsGKELHINLIPN |
| P08047 | S641 | SIGNOR|PSP | SP1 TSFP1 | GKKKQHICHIQGCGKVYGKTsHLRAHLRWHTGERPFMCTWS |
| P08047 | S670 | SIGNOR|PSP | SP1 TSFP1 | HTGERPFMCTWSYCGKRFtRsDELQRHKRtHtGEKKFACPE |
| P08047 | S702 | PSP | SP1 TSFP1 | GEKKFACPECPKRFMRsDHLsKHIKTHQNKKGGPGVALsVG |
| P08047 | T668 | SIGNOR|PSP | SP1 TSFP1 | RWHTGERPFMCTWSYCGKRFtRsDELQRHKRtHtGEKKFAC |
| P08047 | T681 | SIGNOR|PSP | SP1 TSFP1 | SYCGKRFtRsDELQRHKRtHtGEKKFACPECPKRFMRsDHL |
| P08238 | S45 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | MSLIINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKL |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | S48 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKLDsG |
| P08238 | S58 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IFLRELIsNAsDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| P08670 | S34 | SIGNOR|PSP | VIM | MFGGPGtAsRPsssRsYVttsTRtYsLGsALRPstsRsLyA |
| P08670 | S39 | PSP | VIM | GtAsRPsssRsYVttsTRtYsLGsALRPstsRsLyAssPGG |
| P08670 | S56 | PSP | VIM | RtYsLGsALRPstsRsLyAssPGGVyAtRssAVRLRssVPG |
| P08729 | S104 | Sugiyama | KRT7 SCL | LQRVRQEESEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWT |
| P09211 | S185 | SIGNOR | GSTP1 FAEES3 GST3 | VLAPGCLDAFPLLSAYVGRLsARPKLKAFLASPEyVNLPIN |
| P09211 | S43 | SIGNOR | GSTP1 FAEES3 GST3 | ADQGQSWKEEVVTVETWQEGsLKASCLyGQLPKFQDGDLtL |
| P09429 | S181 | PSP | HMGB1 HMG1 | AYRAKGKPDAAKKGVVKAEKsKKKKEEEEDEEDEEDEEEEE |
| P09429 | S39 | PSP | HMGB1 HMG1 | FVQtCREEHKKKHPDAsVNFsEFsKKCsERWKtMsAKEKGK |
| P09429 | S53 | PSP | HMGB1 HMG1 | DAsVNFsEFsKKCsERWKtMsAKEKGKFEDMAKADKARYER |
| P09651 | S360 | Sugiyama | HNRNPA1 HNRPA1 | PyGGGGQyFAKPRNQGGyGGssssssyGsGRRF________ |
| P09651 | S363 | Sugiyama | HNRNPA1 HNRPA1 | GGGQyFAKPRNQGGyGGssssssyGsGRRF___________ |
| P09651 | S368 | Sugiyama | HNRNPA1 HNRPA1 | FAKPRNQGGyGGssssssyGsGRRF________________ |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P09651 | Y366 | Sugiyama | HNRNPA1 HNRPA1 | QyFAKPRNQGGyGGssssssyGsGRRF______________ |
| P12035 | S211 | Sugiyama | KRT3 | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWN |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13639 | S38 | Sugiyama | EEF2 EF2 | NIRNMsVIAHVDHGKStLtDsLVCKAGIIAsARAGEtRFtD |
| P13647 | S181 | Sugiyama | KRT5 | IQRVRTEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P14598 | S303 | SIGNOR | NCF1 NOXO2 SH3PXD1A | sGQDVsQAQRQIKRGAPPRRssIRNAHsIHQRsRKRLsQDA |
| P14598 | S304 | SIGNOR|PSP | NCF1 NOXO2 SH3PXD1A | GQDVsQAQRQIKRGAPPRRssIRNAHsIHQRsRKRLsQDAY |
| P14598 | S315 | SIGNOR|PSP | NCF1 NOXO2 SH3PXD1A | KRGAPPRRssIRNAHsIHQRsRKRLsQDAYRRNsVRFLQQR |
| P14598 | S320 | SIGNOR|PSP | NCF1 NOXO2 SH3PXD1A | PRRssIRNAHsIHQRsRKRLsQDAYRRNsVRFLQQRRRQAR |
| P14598 | S328 | SIGNOR|PSP | NCF1 NOXO2 SH3PXD1A | AHsIHQRsRKRLsQDAYRRNsVRFLQQRRRQARPGPQsPGs |
| P14598 | S359 | SIGNOR | NCF1 NOXO2 SH3PXD1A | ARPGPQsPGsPLEEERQtQRsKPQPAVPPRPsADLILNRCs |
| P14598 | S370 | SIGNOR | NCF1 NOXO2 SH3PXD1A | LEEERQtQRsKPQPAVPPRPsADLILNRCsESTKRKLASAV |
| P14598 | S379 | SIGNOR | NCF1 NOXO2 SH3PXD1A | sKPQPAVPPRPsADLILNRCsESTKRKLASAV_________ |
| P14625 | S106 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | MKLIINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENAL |
| P14625 | S109 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | IINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENALSGN |
| P14625 | S64 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | tDDEVVQREEEAIQLDGLNAsQIRELREKSEKFAFQAEVNR |
| P14625 | S680 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | RIMKAQAYQtGKDIstNyyAsQKKTFEINPRHPLIRDMLRR |
| P15104 | S322 | Sugiyama | GLUL GLNS | GFHETSNINDFSAGVANRsAsIRIPRTVGQEKKGYFEDRRP |
| P17252 | S657 | iPTMNet | PRKCA PKCA PRKACA | LtPPDQLVIANIDQsDFEGFsyVNPQFVHPILQSAV_____ |
| P17844 | S520 | Sugiyama | DDX5 G17P1 HELR HLR1 | GKRGGFNTFRDRENYDRGYssLLKRDFGAKTQNGVYSAANY |
| P18615 | S131 | Sugiyama | NELFE RD RDBP | QRsIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGE |
| P18615 | S135 | Sugiyama | NELFE RD RDBP | sADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEAEG |
| P18615 | Y133 | Sugiyama | NELFE RD RDBP | sIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEA |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P19338 | S460 | Sugiyama | NCL | ADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNST |
| P22626 | S212 | Sugiyama | HNRNPA2B1 HNRPA2B1 | EMQEVQssRsGRGGNFGFGDsRGGGGNFGPGPGsNFRGGsD |
| P23527 | S39 | Sugiyama | H2BC17 H2BFH H2BFN HIST1H2BO | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISSKA |
| P23588 | S122 | Sugiyama | EIF4B | NLPyDVTEESIKEFFRGLNIsAVRLPREPsNPERLKGFGyA |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P26641 | T287 | Sugiyama | EEF1G EF1G PRO1608 | EQALAAEPKAKDPFAHLPKstFVLDEFKRKysNEDtLsVAL |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27448 | T564 | SIGNOR|PSP | MARK3 CTAK1 EMK2 | IssAAtPDRIRFPRGtASRstFHGQPRERRtAtYNGPPAsP |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P28329 | S558 | SIGNOR | CHAT | ALQLAFYRLHRRLVPTYESAsIRRFQEGRVDNIRSAtPEAL |
| P28329 | S594 | SIGNOR | CHAT | tPEALAFVRAVTDHKAAVPAsEKLLLLKDAIRAQTAYTVMA |
| P29317 | S892 | PSP | EPHA2 ECK | DKLIRAPDSLKTLADFDPRVsIRLPstsGsEGVPFRTVsEW |
| P29474 | T495 | SIGNOR | NOS3 | YQPDPWKGSAAKGTGITRKKtFKEVANAVKISASLMGTVMA |
| P29692 | S44 | Sugiyama | EEF1D EF1D | RFyEQMNGPVAGAsRQENGAsVILRDIARARENIQKsLAGs |
| P30086 | S153 | iPTMNet | PEBP1 PBP PEBP | CDEPILsNRsGDHRGKFKVAsFRKKyELRAPVAGtCyQAEW |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P31751 | T309 | SIGNOR | AKT2 | IKITDFGLCKEGISDGATMKtFCGtPEyLAPEVLEDNDyGR |
| P31946 | S132 | ELM|iPTMNet | YWHAB | TQPESKVFyLKMKGDYFRyLsEVAsGDNKQTtVsNsQQAyQ |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31946 | T143 | SIGNOR|iPTMNet | YWHAB | MKGDYFRyLsEVAsGDNKQTtVsNsQQAyQEAFEIsKKEMQ |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P33778 | S39 | Sugiyama | H2BC3 H2BFF HIST1H2BB | ITKAQKKDGKKRKRsRKEsysIyVyKVLKQVHPDTGISSKA |
| P35222 | S45 | SIGNOR|PSP | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | WQQQsyLDsGIHsGATtTAPsLsGKGNPEEEDVDTsQVLyE |
| P35222 | S552 | SIGNOR | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | AIPRLVQLLVRAHQDtQRRtsMGGtQQQFVEGVRMEEIVEG |
| P35222 | S675 | SIGNOR | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | AAAVLFRMSEDKPQDyKKRLsVELtssLFRTEPMAWNETAD |
| P35236 | S246 | SIGNOR | PTPN7 | KECPEYTVRQLTIQYQEERRsVKHILFSAWPDHQTPESAGP |
| P35269 | T154 | Sugiyama | GTF2F1 RAP74 | AFEAFPVHNWYNFTPLARHRtLtAEEAEEEWERRNKVLNHF |
| P35568 | S1101 | SIGNOR | IRS1 | RNQSAKVIRADPQGCRRRHssEtFsstPSATRVGNTVPFGA |
| P35568 | S307 | SIGNOR | IRS1 | HHLNNPPPSQVGLTRRsRtEsItAtsPAsMVGGKPGsFRVR |
| P35568 | S323 | SIGNOR|ELM|PSP | IRS1 | sRtEsItAtsPAsMVGGKPGsFRVRAssDGEGtMsRPAsVD |
| P35568 | S441 | PSP | IRS1 | SDGGFISSDEYGSSPCDFRSsFRsVtPDsLGHtPPARGEEE |
| P35580 | S1935 | PSP | MYH10 | EGLSREVSTLKNRLRRGGPIsFsssRSGRRQLHLEGAsLEL |
| P35580 | S1937 | SIGNOR|PSP | MYH10 | LSREVSTLKNRLRRGGPIsFsssRSGRRQLHLEGAsLELsD |
| P35580 | S1956 | PSP | MYH10 | FsssRSGRRQLHLEGAsLELsDDDtEsKtsDVNEtQPPQsE |
| P35611 | S5 | ELM | ADD1 ADDA | ________________MNGDsRAAVVtsPPPttAPHKERyF |
| P35611 | S726 | SIGNOR|PSP | ADD1 ADDA | GsDGSPGKSPsKKKKKFRtPsFLKKSKKKSDS_________ |
| P35612 | S713 | SIGNOR|PSP | ADD2 ADDB | sPEGsPsKsPsKKKKKFRTPsFLKKSKKKEKVEs_______ |
| P35908 | S191 | Sugiyama | KRT2 KRT2A KRT2E | IQNVKAQEREQIKTLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| P36578 | S87 | Sugiyama | RPL4 RPL1 | WGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAPTKT |
| P36578 | T84 | Sugiyama | RPL4 RPL1 | AEsWGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAP |
| P37108 | S25 | Sugiyama | SRP14 | EsEQFLtELTRLFQKCRTSGsVyItLKKYDGRTKPIPKKGt |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P38646 | T116 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | DGERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKD |
| P38646 | T120 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | LVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIKNV |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P39023 | S265 | Sugiyama | RPL3 OK/SW-cl.32 | HRGLRKVACIGAWHPARVAFsVARAGQKGYHHRTEINKKIY |
| P41594 | S840 | SIGNOR|iPTMNet | GRM5 GPRC1E MGLUR5 | PKVYIILAKPERNVRSAFTTstVVRMHVGDGKSSSAASRSS |
| P41594 | T841 | SIGNOR | GRM5 GPRC1E MGLUR5 | KVYIILAKPERNVRSAFTTstVVRMHVGDGKSSSAASRSSS |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46060 | S24 | Sugiyama | RANGAP1 KIAA1835 SD | EDIAKLAETLAKTQVAGGQLsFKGKSLKLNTAEDAKDVIKE |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46779 | S115 | Sugiyama | RPL28 | HMIRKNKYRPDLRMAAIRRAsAILRSQKPVMVKRKRTRPTK |
| P46783 | S146 | Sugiyama | RPS10 | TYRRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ_ |
| P46937 | S109 | SIGNOR|PSP | YAP1 YAP65 | RKLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssP |
| P46937 | T110 | SIGNOR|PSP | YAP1 YAP65 | KLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssPA |
| P47712 | S727 | Sugiyama | PLA2G4A CPLA2 PLA2G4 | VIKEAMVESIEyRRQNPsRCsVsLsNVEARRFFNKEFLSKP |
| P47712 | T376 | SIGNOR|PSP | PLA2G4A CPLA2 PLA2G4 | MAKYGTFMAPDLFGSKFFMGtVVKKYEENPLHFLMGVWGSA |
| P48668 | S176 | Sugiyama | KRT6C KRT6E | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P49757 | S295 | iPTMNet | NUMB C14orf41 | GsFRGFPALsQKMSPFKRQLsLRINELPstMQRKTDFPIKN |
| P49757 | S7 | iPTMNet|PSP | NUMB C14orf41 | ______________MNKLRQsFRRKKDVyVPEASRPHQWQT |
| P49768 | S346 | SIGNOR|iPTMNet | PSEN1 AD3 PS1 PSNL1 | DtVAENDDGGFsEEWEAQRDsHLGPHRstPEsRAAVQELss |
| P49841 | S147 | PSP | GSK3B | YLNLVLDYVPETVYRVARHYsRAKQTLPVIYVKLYMYQLFR |
| P49841 | S9 | SIGNOR|PSP | GSK3B | ____________MSGRPRttsFAEsCKPVQQPsAFGsMKVS |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P51991 | S375 | Sugiyama | HNRNPA3 HNRPA3 | ssGsPyGGGyGsGGGsGGyGsRRF_________________ |
| P52742 | S308 | Sugiyama | ZNF135 ZNF61 ZNF78L1 | HQRTHTGEKPYECSECGKSFsFRSSFSQHERTHTGEKPYEC |
| P53004 | S149 | PSP | BLVRA BLVR BVR | LMEEFAFLKKEVVGKDLLKGsLLFTAGPLEEERFGFPAFSG |
| P53004 | S230 | PSP | BLVRA BLVR BVR | KsPLSWIEEKGPGLKRNRyLsFHFKsGsLENVPNVGVNKNI |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P55040 | S261 | ELM|PSP | GEM KIR | LRRDSKEKNERRLAYQKRKEsMPRKARRFWGKIVAKNNKNM |
| P55196 | S216 | Sugiyama | AFDN AF6 MLLT4 | SRLAAEVYKDMPETSFTRtIsNPEVVMKRRRQQKLEKRMQE |
| P55211 | S144 | SIGNOR|ELM|iPTMNet|PSP | CASP9 MCH6 | EtPRPVDIGSGGFGDVGALEsLRGNADLAyILSMEPCGHCL |
| P57053 | S39 | Sugiyama | H2BC12L H2BFS H2BS1 | VTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P58876 | S39 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60484 | S380 | PSP | PTEN MMAC1 TEP1 | SSsTSVtPDVsDNEPDHyRYsDttDsDPENEPFDEDQHtQI |
| P60484 | T382 | PSP | PTEN MMAC1 TEP1 | sTSVtPDVsDNEPDHyRYsDttDsDPENEPFDEDQHtQItK |
| P60484 | T383 | PSP | PTEN MMAC1 TEP1 | TSVtPDVsDNEPDHyRYsDttDsDPENEPFDEDQHtQItKV |
| P61247 | S237 | Sugiyama | RPS3A FTE1 MFTL | MLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGyE |
| P61254 | S9 | Sugiyama | RPL26 | ____________MKFNPFVtsDRsKNRKRHFNAPsHIRRKI |
| P61254 | T8 | Sugiyama | RPL26 | _____________MKFNPFVtsDRsKNRKRHFNAPsHIRRK |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61587 | S210 | PSP | RND3 ARHE RHO8 RHOE | FHVATLACVNKTNKNVKRNKsQRATKRIsHMPSRPELSAVA |
| P61978 | S75 | Sugiyama | HNRNPK HNRPK | GAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIE |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P62241 | S115 | Sugiyama | RPS8 OK/SW-cl.83 | TLVKNCIVLIDStPYRQWyEsHyALPLGRKKGAKLtPEEEE |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62263 | S139 | Sugiyama | RPS14 PRO2640 | LARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL________ |
| P62269 | S96 | Sugiyama | RPS18 D6S218E | QYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLKK |
| P62273 | S9 | Sugiyama | RPS29 | ____________MGHQQLyWsHPRKFGQGSRSCRVCSNRHG |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62312 | S74 | Sugiyama | LSM6 | GQLKNKyGDAFIRGNNVLyIstQKRRM______________ |
| P62701 | T247 | Sugiyama | RPS4X CCG2 RPS4 SCAR | VIGKGNKPWIsLPRGKGIRLtIAEERDKRLAAKQSSG____ |
| P62807 | S39 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | VTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIssKA |
| P62851 | S74 | Sugiyama | RPS25 | tyDKLCKEVPNYKLItPAVVsERLKIRGSLARAALQELLsK |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | S14 | Sugiyama | RPL8 | _______MGRVIRGQRKGAGsVFRAHVKHRKGAARLRAVDF |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | T143 | Sugiyama | RPL8 | RGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANR |
| P62917 | T146 | Sugiyama | RPL8 | LARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANRAVV |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P62979 | S134 | Sugiyama | RPS27A UBA80 UBCEP1 | IsRLRRECPsDECGAGVFMAsHFDRHyCGKCCLtyCFNKPE |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P67809 | Y196 | Sugiyama | YBX1 NSEP1 YB1 | sAPEGQAQQRRPyRRRRFPPyyMRRPYGRRPQysNPPVQGE |
| P68104 | T432 | Sugiyama | EEF1A1 EEF1A EF1A LENG7 | VEsFSDyPPLGRFAVRDMRQtVAVGVIKAVDKKAAGAGKVT |
| P78563 | S211 | SIGNOR|PSP | ADARB1 ADAR2 DRADA2 RED1 | YVGSNGDDSFSSSGDLSLSAsPVPAsLAQPPLPVLPPFPPP |
| P78563 | S216 | SIGNOR|PSP | ADARB1 ADAR2 DRADA2 RED1 | GDDSFSSSGDLSLSAsPVPAsLAQPPLPVLPPFPPPSGKNP |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P84098 | S12 | Sugiyama | RPL19 | _________MSMLRLQKRLAssVLRCGKKKVWLDPNEtNEI |
| P84098 | S122 | Sugiyama | RPL19 | LRRLLRRYRESKKIDRHMyHsLyLKVKGNVFKNKRILMEHI |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q01546 | S196 | Sugiyama | KRT76 KRT2B KRT2P | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWE |
| Q02543 | S123 | Sugiyama | RPL18A | AGAVtQCyRDMGARHRARAHsIQIMKVEEIAASKCRRPAVK |
| Q04206 | S311 | SIGNOR|ELM|iPTMNet|PSP | RELA NFKB3 | DTDDRHRIEEKRKRtYEtFKsIMKKsPFSGPTDPRPPPRRI |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q05513 | S148 | Sugiyama | PRKCZ PKC2 | ANGHLFQAKRFNRRAyCGQCsERIWGLARQGYRCINCKLLV |
| Q05513 | S223 | Sugiyama | PRKCZ PKC2 | DLPsEEtDGIAYISSSRKHDsIKDDsEDLKPVIDGMDGIKI |
| Q05513 | S228 | Sugiyama | PRKCZ PKC2 | EtDGIAYISSSRKHDsIKDDsEDLKPVIDGMDGIKISQGLG |
| Q05513 | S482 | Sugiyama | PRKCZ PKC2 | TEDYLFQVILEKPIRIPRFLsVKAsHVLKGFLNKDPKERLG |
| Q05513 | S486 | Sugiyama | PRKCZ PKC2 | LFQVILEKPIRIPRFLsVKAsHVLKGFLNKDPKERLGCRPQ |
| Q05513 | S573 | Sugiyama | PRKCZ PKC2 | TSEPVQLtPDDEDAIKRIDQsEFEGFEYINPLLLSTEEsV_ |
| Q05513 | T560 | SIGNOR|ELM|iPTMNet | PRKCZ PKC2 | TDDYGLDNFDTQFTSEPVQLtPDDEDAIKRIDQsEFEGFEY |
| Q05513 | Y143 | Sugiyama | PRKCZ PKC2 | RKLYRANGHLFQAKRFNRRAyCGQCsERIWGLARQGYRCIN |
| Q05639 | T432 | Sugiyama | EEF1A2 EEF1AL STN | VESFSQYPPLGRFAVRDMRQtVAVGVIKNVEKKSGGAGKVT |
| Q05655 | S664 | iPTMNet | PRKCD PKCD | LsysDKNLIDsMDQsAFAGFsFVNPKFEHLLED________ |
| Q07812 | S184 | SIGNOR|PSP | BAX BCL2L4 | YFGtPTWQtVtIFVAGVLTAsLtIWKKMG____________ |
| Q12933 | S55 | SIGNOR|PSP | TRAF2 TRAP3 | SACRNVLRRPFQAQCGHRYCsFCLASILSSGPQNCAACVHE |
| Q13118 | S384 | PSP | KLF10 TIEG TIEG1 | SRIRSHICSHPGCGKTYFKSsHLKAHTRTHTGEKPFSCSWK |
| Q13118 | T445 | PSP | KLF10 TIEG TIEG1 | GEKKFACPMCDRRFMRSDHLtKHARRHLSAKKLPNWQMEVS |
| Q14152 | S988 | Sugiyama | EIF3A EIF3S10 KIAA0139 | PRRGPEEDRFsRRGADDDRPsWRNTDDDRPPRRIADEDRGN |
| Q14568 | S53 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | IINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDSG |
| Q14CN4 | S138 | Sugiyama | KRT72 K6IRS2 KB35 KRT6 KRT6IRS2 | IQRVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWN |
| Q15084 | S389 | Sugiyama | PDIA6 ERP5 P5 TXNDC7 | FALLKGsFsEQGINEFLRELsFGRGstAPVGGGAFPtIVER |
| Q15109 | S391 | PSP | AGER RAGE | EERKAPENQEEEEERAELNQsEEPEAGEssTGGP_______ |
| Q15185 | S72 | Sugiyama | PTGES3 P23 TEBP | EIDLFHCIDPNDsKHKRtDRsILCCLRKGEsGQsWPRLTKE |
| Q15466 | T55 | PSP | NR0B2 SHP | PRSRCLCRQHRPVQLCAPHRtCREALDVLAKTVAFLRNLPS |
| Q15831 | S307 | SIGNOR|PSP | STK11 LKB1 PJS | KGMLEYEPAKRFSIRQIRQHsWFRKKHPPAEAPVPIPPsPD |
| Q15831 | S428 | SIGNOR|PSP | STK11 LKB1 PJS | GRAPNPARKACSASSKIRRLsACKQQ_______________ |
| Q16236 | S40 | PSP | NFE2L2 NRF2 | IDILWRQDIDLGVSREVFDFsQRRKEYELEKQKKLEKERQE |
| Q16612 | S59 | SIGNOR|PSP | NREP C5orf13 P311 | KKNDETNAASLTPLGSSELRsPRISYLHFF___________ |
| Q16625 | T403 | PSP | OCLN | AKGRAGRSKRTEQDHyEtDyttGGEsCDELEEDWIREYPPI |
| Q16625 | T404 | PSP | OCLN | KGRAGRSKRTEQDHyEtDyttGGEsCDELEEDWIREYPPIt |
| Q16625 | T424 | PSP | OCLN | tGGEsCDELEEDWIREYPPItSDQQRQLYKRNFDtGLQEyK |
| Q16625 | T438 | PSP | OCLN | REYPPItSDQQRQLYKRNFDtGLQEyKsLQSELDEINKELS |
| Q16778 | S39 | Sugiyama | H2BC21 H2BFQ HIST2H2BE | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGIssKA |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q3SY84 | S143 | Sugiyama | KRT71 K6IRS1 KB34 KRT6IRS1 | IQKVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q58FF6 | S34 | Sugiyama | HSP90AB4P | IFLQELISNASDALDKIRyEsLtDPsKLDGGKELKIDIIPN |
| Q58FF7 | S58 | Sugiyama | HSP90AB3P HSP90BC | IFLQELISNASDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| Q58FF8 | S58 | Sugiyama | HSP90AB2P HSP90BB | IFLWELISNASDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| Q5JVS0 | T354 | SIGNOR|iPTMNet|PSP | HABP4 | MVKDDYEDDSHVFRKPANDItSQLEINFGNLPRPGRGARGG |
| Q5JVS0 | T375 | SIGNOR|iPTMNet|PSP | HABP4 | SQLEINFGNLPRPGRGARGGtRGGRGRIRRAENYGPRAEVV |
| Q5QNW6 | S39 | Sugiyama | H2BC18 HIST2H2BF | VTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q5VTE0 | T432 | Sugiyama | EEF1A1P5 EEF1AL3 | VEsFSDyPPLGRFAVRDMRQtVAVGVIKAVDKKAAGAGKVT |
| Q5XKE5 | S155 | Sugiyama | KRT79 K6L KB38 KRT6L | IQRVRTQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| Q6DN03 | S39 | Sugiyama | H2BC20P HIST2H2BC | VTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWCKA |
| Q6DRA6 | S39 | Sugiyama | H2BC19P HIST2H2BD | VTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWCKA |
| Q6STE5 | S247 | PSP | SMARCD3 BAF60C | HRTPTTQETDGFQVKRPGDLsVRCTLLLMLDYQPPQFKLDP |
| Q6ZMR3 | S167 | Sugiyama | LDHAL6A LDHL2 | AWKLSGFPKNRVIGsGCNLDsARFRYFIGQRLGIHSESCHG |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q7KZI7 | T596 | SIGNOR|PSP | MARK2 EMK1 | sssGGAPDRTNFPRGVssRstFHAGQLRQVRDQQNLPyGVt |
| Q7RTS7 | S153 | Sugiyama | KRT74 K6IRS4 KB37 KRT5C KRT6IRS4 | IQKVRAQEREQIKVLNDKFAsFIDKVRFLEQQNQVLETKWE |
| Q7Z417 | S655 | Sugiyama | NUFIP2 KIAA1321 PIG1 | LGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsIWNL |
| Q7Z794 | S177 | Sugiyama | KRT77 KRT1B | IQRIKTQEREQIMVLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| Q86V81 | S239 | Sugiyama | ALYREF ALY BEF THOC4 | tRGGARGRGRGAGRNSKQQLsAEELDAQLDAyNARMDts__ |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86Y46 | S145 | Sugiyama | KRT73 K6IRS3 KB36 KRT6IRS3 | IQKVRAQEREQIKVLNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q8IWX8 | S904 | Sugiyama | CHERP DAN26 SCAF6 | KGVGVALDDPyENyRRNKsysFIARMKARDECK________ |
| Q8IX03 | S975 | SIGNOR|iPTMNet|PSP | WWC1 KIAA0869 KIBRA | KPPFVRNSLERRSVRMKRPSsVKsLRSERLIRTSLDLELDL |
| Q8IX03 | S978 | SIGNOR|iPTMNet|PSP | WWC1 KIAA0869 KIBRA | FVRNSLERRSVRMKRPSsVKsLRSERLIRTSLDLELDLQAT |
| Q8IXH6 | S208 | Sugiyama | TP53INP2 C20orf110 DOR PINH | AVQRQNRARESRPRRSKNQSsFIyQPCQRQFNY________ |
| Q8IZ21 | S590 | Sugiyama | PHACTR4 PRO2963 | SKEEWNEIRHQIGNTLIRRLsQRPtPEELEQRNILQPKNEA |
| Q8N257 | S39 | Sugiyama | H2BC26 H2BU1 HIST3H2BB | VTKAQKKDGKKRKRGRKEsysIyVyKVLKQVHPDTGIssKA |
| Q8N2W9 | S18 | SIGNOR|PSP | PIAS4 PIASG | ___MAAELVEAKNMVMSFRVsDLQMLLGFVGRSKSGLKHEL |
| Q8NBJ7 | S256 | Sugiyama | SUMF2 PSEC0171 UNQ1968/PRO4500 | EWTASPYQAAEQDMRVLRGAsWIDtADGsANHRARVttRMG |
| Q8TD47 | T247 | Sugiyama | RPS4Y2 RPS4Y2P | VIGNGNKPWISLPRGKGIRLtIAEERDKRLAAKQSSG____ |
| Q8TEW0 | S827 | SIGNOR | PARD3 PAR3 PAR3A | sLsPDVDPVLAFQREGFGRQsMsEKRtKQFsDAsQLDFVKT |
| Q8WVC0 | T477 | Sugiyama | LEO1 RDL | FDVYKAPLQGDHNHLFIRQGtGLQGQAVFKTKLTFRPHstD |
| Q92890 | S299 | Sugiyama | UFD1 UFD1L | KKVEEDEAGGRFVAFsGEGQsLRKKGRKP____________ |
| Q93079 | S39 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q96A00 | T38 | SIGNOR|ELM|iPTMNet|PSP | PPP1R14A CPI17 PPP1INL | SRARGPGGsPGGLQKRHARVtVKYDRRELQRRLDVEKWIDG |
| Q96RI1 | T456 | SIGNOR | NR1H4 BAR FXR HRR1 RIP14 | HQPENPQHFACLLGRLTELRtFNHHHAEMLMSWRVNDHKFT |
| Q99613 | S639 | Sugiyama | EIF3C EIF3S8 | CAFRQGLTKDAHNALLDIQssGRAKELLGQGLLLRSLQERN |
| Q99700 | S505 | Sugiyama | ATXN2 ATX2 SCA2 TNRC13 | SINTRENKYIPPGQRNREVIsWGsGRQNsPRMGQPGsGSMP |
| Q99700 | S508 | Sugiyama | ATXN2 ATX2 SCA2 TNRC13 | TRENKYIPPGQRNREVIsWGsGRQNsPRMGQPGsGSMPSRs |
| Q99848 | S270 | Sugiyama | EBNA1BP2 EBP2 | FGGKKKGSKWNtREsyDDVssFRAKTAHGRGLKRPGKKGSN |
| Q99877 | S39 | Sugiyama | H2BC15 H2BFD HIST1H2BN | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99879 | S39 | Sugiyama | H2BC14 H2BFE HIST1H2BM | INKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99880 | S39 | Sugiyama | H2BC13 H2BFC HIST1H2BL | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q9BQ52 | S212 | Sugiyama | ELAC2 HPC2 | GKHQPWQsPERPLsRLsPERssDsEsNENEPHLPHGVsQRR |
| Q9BUJ2 | S512 | Sugiyama | HNRNPUL1 E1BAP5 HNRPUL1 | IQIAARKKRNyILDQtNVyGsAQRRKMRPFEGFQRKAIVIC |
| Q9GZQ8 | T50 | SIGNOR|PSP | MAP1LC3B MAP1ALC3 | KIPVIIERYKGEKQLPVLDKtKFLVPDHVNMSELIKIIRRR |
| Q9NPB6 | S345 | SIGNOR|PSP | PARD6A PAR6A | DQEQASSGWGSRIRGDGSGFsL___________________ |
| Q9NQ39 | S157 | Sugiyama | RPS10P5 RPS10L | TYRRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ_ |
| Q9NSB2 | S178 | Sugiyama | KRT84 KRTHB4 | AQRVKKDEKEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWS |
| Q9NYF8 | S319 | Sugiyama | BCLAF1 BTF KIAA0164 | RsPAKtIAPQNAPRDEsRGRssFyPDGGDQETAKtGKFLKR |
| Q9P286 | S99 | PSP | PAK5 KIAA1264 PAK7 | ETSINGLLEDFDNISVTRSNsLRKESPPTPDQGASSHGPGH |
| Q9P2T1 | S37 | Sugiyama | GMPR2 | LRPKRSTLKsRsEVDLTRSFsFRNSKQTYSGVPIIAANMDT |
| Q9UBR2 | S78 | Sugiyama | CTSZ | SPADLPKSWDWRNVDGVNyAsItRNQHIPQYCGSCWAHAST |
| Q9UBS0 | S473 | ELM|PSP | RPS6KB2 STK14B | PPPPSTTAPLPIRPPSGTKKsKRGRGRPGR___________ |
| Q9UJZ1 | S17 | PSP | STOML2 SLP2 HSPC108 | ____MLARAARGTGALLLRGsLLASGRAPRRASSGLPRNTV |
| Q9ULX6 | T267 | Sugiyama | AKAP8L NAKAP NAKAP95 HRIHFB2018 | RFGFGFGNGMKQMRRTWKTWtTADFRTKKKKRKQGGsPDEP |
| Q9UNX3 | S9 | Sugiyama | RPL26L1 RPL26P1 | ____________MKFNPFVtsDRsKNRKRHFNAPSHVRRKI |
| Q9UNX3 | T8 | Sugiyama | RPL26L1 RPL26P1 | _____________MKFNPFVtsDRsKNRKRHFNAPSHVRRK |
| Q9UQ35 | S2692 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ERRSRSPRKPIDsLRDsRsLsysPVERRRPsPQPsPRDQQS |
| Q9Y243 | S472 | SIGNOR | AKT3 PKBG | YDEDGMDCMDNERRPHFPQFsysAsGRE_____________ |
| Q9Y243 | T305 | SIGNOR | AKT3 PKBG | IKITDFGLCKEGITDAATMKtFCGtPEyLAPEVLEDNDyGR |
| Q9Y2B0 | S55 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDELEWEIAQVDPKKTIQMGsFRINPDGsQsVVEVPyARsE |
| Q9Y2W1 | S257 | Sugiyama | THRAP3 BCLAF2 TRAP150 | sAVsELsPRERsPALKsPLQsVVVRRRsPRPsPVPKPSPPL |
| Q9Y6Q9 | S1033 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | GMLSMEQVSHGTQNRPLLRNsLDDLVGPPsNLEGQsDERAL |
| Q9Y6Q9 | S1042 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | HGTQNRPLLRNsLDDLVGPPsNLEGQsDERALLDQLHtLLs |
| Q9Y6Q9 | S1048 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | PLLRNsLDDLVGPPsNLEGQsDERALLDQLHtLLsNtDAtG |
| Q9Y6Q9 | S1062 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | sNLEGQsDERALLDQLHtLLsNtDAtGLEEIDRALGIPELV |
| Q9Y6Q9 | T1059 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | GPPsNLEGQsDERALLDQLHtLLsNtDAtGLEEIDRALGIP |
| Q9Y6Q9 | T1064 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | LEGQsDERALLDQLHtLLsNtDAtGLEEIDRALGIPELVNQ |
| Q9Y6Q9 | T1067 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | QsDERALLDQLHtLLsNtDAtGLEEIDRALGIPELVNQGQA |
| Q9Y6Q9 | T1114 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | AFQGQEAAVMMDQKAGLYGQtYPAQGPPMQGGFHLQGQSPS |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 2.377654e-12 | 11.624 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 9.241830e-12 | 11.034 | 1 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.751889e-10 | 9.560 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 4.973149e-10 | 9.303 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.726899e-09 | 8.564 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.377127e-09 | 8.359 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.037072e-08 | 7.691 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 3.084848e-08 | 7.511 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.018792e-07 | 6.992 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 9.500780e-08 | 7.022 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.620190e-06 | 5.790 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.922077e-06 | 5.716 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.164920e-06 | 5.665 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.164920e-06 | 5.665 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.399522e-06 | 5.620 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.695587e-06 | 5.569 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 4.550983e-06 | 5.342 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.922550e-06 | 5.308 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.314279e-06 | 5.275 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.683799e-06 | 5.245 | 1 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.947437e-06 | 5.226 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 8.624537e-06 | 5.064 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.092765e-05 | 4.961 | 1 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.296699e-05 | 4.887 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.396844e-05 | 4.855 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.343540e-05 | 4.476 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.419429e-05 | 4.466 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.838364e-05 | 4.416 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.808437e-05 | 4.236 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 5.803265e-05 | 4.236 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.233024e-05 | 4.205 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 6.377392e-05 | 4.195 | 1 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 6.617552e-05 | 4.179 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 6.955174e-05 | 4.158 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 7.789250e-05 | 4.109 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 8.029248e-05 | 4.095 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 8.777062e-05 | 4.057 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 9.856024e-05 | 4.006 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.027907e-04 | 3.988 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.108945e-04 | 3.955 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.117941e-04 | 3.952 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.210953e-04 | 3.917 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.418797e-04 | 3.848 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.389614e-04 | 3.857 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.389614e-04 | 3.857 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.499026e-04 | 3.824 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.689444e-04 | 3.772 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.962254e-04 | 3.707 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.156064e-04 | 3.666 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.156064e-04 | 3.666 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.791986e-04 | 3.554 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.927146e-04 | 3.534 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.402583e-04 | 3.468 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 3.387788e-04 | 3.470 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.808975e-04 | 3.419 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.763276e-04 | 3.424 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 3.886527e-04 | 3.410 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.117452e-04 | 3.385 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.124203e-04 | 3.385 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.416495e-04 | 3.355 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 4.707047e-04 | 3.327 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 4.969371e-04 | 3.304 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 4.969371e-04 | 3.304 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.703857e-04 | 3.244 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 5.733734e-04 | 3.242 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 6.355440e-04 | 3.197 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.566428e-04 | 3.183 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.413445e-04 | 3.130 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 7.125942e-04 | 3.147 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 7.586515e-04 | 3.120 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 7.586515e-04 | 3.120 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 8.365151e-04 | 3.078 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 8.920716e-04 | 3.050 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 8.943251e-04 | 3.049 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 9.510516e-04 | 3.022 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.012461e-03 | 2.995 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.022827e-03 | 2.990 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.180061e-03 | 2.928 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.199423e-03 | 2.921 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.247204e-03 | 2.904 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.235637e-03 | 2.908 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.277500e-03 | 2.894 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.254862e-03 | 2.901 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.289917e-03 | 2.889 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.315685e-03 | 2.881 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.443942e-03 | 2.840 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.458978e-03 | 2.836 | 1 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.588520e-03 | 2.799 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.786190e-03 | 2.748 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.808881e-03 | 2.743 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.808881e-03 | 2.743 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.843860e-03 | 2.734 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.986443e-03 | 2.702 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.987314e-03 | 2.702 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.987883e-03 | 2.702 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.097321e-03 | 2.678 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.240807e-03 | 2.650 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.309612e-03 | 2.636 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.215256e-03 | 2.655 | 1 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.390140e-03 | 2.622 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.391230e-03 | 2.621 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 2.676446e-03 | 2.572 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.676446e-03 | 2.572 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.676446e-03 | 2.572 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.676446e-03 | 2.572 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.676446e-03 | 2.572 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.676446e-03 | 2.572 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 2.981802e-03 | 2.526 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.900103e-03 | 2.538 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.900103e-03 | 2.538 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.900103e-03 | 2.538 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.900103e-03 | 2.538 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.998524e-03 | 2.523 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 3.003618e-03 | 2.522 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.040217e-03 | 2.517 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.220253e-03 | 2.492 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 3.247739e-03 | 2.488 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.247739e-03 | 2.488 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.610999e-03 | 2.442 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.610999e-03 | 2.442 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.493653e-03 | 2.457 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.738254e-03 | 2.427 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 4.138270e-03 | 2.383 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 4.312994e-03 | 2.365 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.312994e-03 | 2.365 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.376518e-03 | 2.359 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 4.447357e-03 | 2.352 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.516818e-03 | 2.345 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.516818e-03 | 2.345 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.829271e-03 | 2.316 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.829271e-03 | 2.316 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.829271e-03 | 2.316 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.829271e-03 | 2.316 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 4.880388e-03 | 2.312 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.409075e-03 | 2.267 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 5.269159e-03 | 2.278 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.269159e-03 | 2.278 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 5.409075e-03 | 2.267 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.238891e-03 | 2.281 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 5.269159e-03 | 2.278 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.818064e-03 | 2.235 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 5.873753e-03 | 2.231 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 5.873753e-03 | 2.231 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 5.915308e-03 | 2.228 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 5.946369e-03 | 2.226 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 6.043753e-03 | 2.219 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 6.043753e-03 | 2.219 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 6.107543e-03 | 2.214 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 6.678288e-03 | 2.175 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 6.678288e-03 | 2.175 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 6.769707e-03 | 2.169 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 6.769707e-03 | 2.169 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.499604e-03 | 2.187 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.781974e-03 | 2.169 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 6.928458e-03 | 2.159 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 7.296651e-03 | 2.137 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.918178e-03 | 2.160 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.336304e-03 | 2.135 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 6.907840e-03 | 2.161 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 7.336304e-03 | 2.135 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.234020e-03 | 2.141 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 7.495211e-03 | 2.125 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 7.119129e-03 | 2.148 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.985898e-03 | 2.156 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 6.928458e-03 | 2.159 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 6.899647e-03 | 2.161 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.000908e-03 | 2.097 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 8.072561e-03 | 2.093 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 8.482442e-03 | 2.071 | 1 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 8.510249e-03 | 2.070 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 8.784421e-03 | 2.056 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 8.964622e-03 | 2.047 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 9.337483e-03 | 2.030 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 9.365485e-03 | 2.028 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 9.454358e-03 | 2.024 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 9.870761e-03 | 2.006 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 9.638285e-03 | 2.016 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.638285e-03 | 2.016 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 9.975430e-03 | 2.001 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.010774e-02 | 1.995 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.062049e-02 | 1.974 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.041483e-02 | 1.982 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.005208e-02 | 1.998 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.005208e-02 | 1.998 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 9.975430e-03 | 2.001 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.067338e-02 | 1.972 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 1.071135e-02 | 1.970 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 1.071135e-02 | 1.970 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 1.071135e-02 | 1.970 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 1.087236e-02 | 1.964 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.150961e-02 | 1.939 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 1.192571e-02 | 1.924 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 1.192571e-02 | 1.924 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.192571e-02 | 1.924 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.192571e-02 | 1.924 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.216568e-02 | 1.915 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.217652e-02 | 1.914 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.217652e-02 | 1.914 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.223598e-02 | 1.912 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.226789e-02 | 1.911 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.400064e-02 | 1.854 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.400064e-02 | 1.854 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.323886e-02 | 1.878 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.307255e-02 | 1.884 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.400064e-02 | 1.854 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.260466e-02 | 1.899 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.245976e-02 | 1.904 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.260466e-02 | 1.899 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.295114e-02 | 1.888 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.406010e-02 | 1.852 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.416259e-02 | 1.849 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.456221e-02 | 1.837 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.542017e-02 | 1.812 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.608466e-02 | 1.794 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.615355e-02 | 1.792 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.615355e-02 | 1.792 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.615355e-02 | 1.792 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.632475e-02 | 1.787 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.632475e-02 | 1.787 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.666010e-02 | 1.778 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 1.666010e-02 | 1.778 | 1 | 1 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.684806e-02 | 1.773 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.701102e-02 | 1.769 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.714024e-02 | 1.766 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.754200e-02 | 1.756 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.777819e-02 | 1.750 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.057822e-02 | 1.687 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.019551e-02 | 1.695 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.057822e-02 | 1.687 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.057822e-02 | 1.687 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.032510e-02 | 1.692 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 1.975931e-02 | 1.704 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 1.975931e-02 | 1.704 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.950546e-02 | 1.710 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.862127e-02 | 1.730 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.057822e-02 | 1.687 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.847498e-02 | 1.733 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 2.105383e-02 | 1.677 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 2.105383e-02 | 1.677 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 2.118697e-02 | 1.674 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 2.118697e-02 | 1.674 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 2.118697e-02 | 1.674 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 2.118697e-02 | 1.674 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.173205e-02 | 1.663 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.173205e-02 | 1.663 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 2.193784e-02 | 1.659 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 2.232815e-02 | 1.651 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.232815e-02 | 1.651 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.232815e-02 | 1.651 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 2.232815e-02 | 1.651 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 2.282637e-02 | 1.642 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.313525e-02 | 1.636 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 2.317888e-02 | 1.635 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 2.317888e-02 | 1.635 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 2.317888e-02 | 1.635 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.346737e-02 | 1.630 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.560019e-02 | 1.592 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.424934e-02 | 1.615 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.505304e-02 | 1.601 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.539534e-02 | 1.595 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.539534e-02 | 1.595 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.505304e-02 | 1.601 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.735071e-02 | 1.563 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.568035e-02 | 1.590 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.505304e-02 | 1.601 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.539534e-02 | 1.595 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.539538e-02 | 1.595 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.539538e-02 | 1.595 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 2.453736e-02 | 1.610 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.357557e-02 | 1.628 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.593902e-02 | 1.586 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.766952e-02 | 1.558 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 2.874334e-02 | 1.541 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.895284e-02 | 1.538 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.911556e-02 | 1.536 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.921421e-02 | 1.534 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 2.940665e-02 | 1.532 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.940665e-02 | 1.532 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.940665e-02 | 1.532 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.940665e-02 | 1.532 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 3.016638e-02 | 1.520 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 3.016638e-02 | 1.520 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.049152e-02 | 1.516 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.054052e-02 | 1.515 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.054971e-02 | 1.515 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.072170e-02 | 1.513 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 3.081651e-02 | 1.511 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 3.141851e-02 | 1.503 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.141851e-02 | 1.503 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 3.141851e-02 | 1.503 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 3.141851e-02 | 1.503 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 3.141851e-02 | 1.503 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 3.141851e-02 | 1.503 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.141851e-02 | 1.503 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.192467e-02 | 1.496 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.193933e-02 | 1.496 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 3.459753e-02 | 1.461 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 3.459753e-02 | 1.461 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 3.459753e-02 | 1.461 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 3.459753e-02 | 1.461 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 3.459753e-02 | 1.461 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 3.459753e-02 | 1.461 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 3.459753e-02 | 1.461 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 3.459753e-02 | 1.461 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 3.459753e-02 | 1.461 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 3.703362e-02 | 1.431 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 3.703362e-02 | 1.431 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 3.703362e-02 | 1.431 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 3.930282e-02 | 1.406 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.930282e-02 | 1.406 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 3.930282e-02 | 1.406 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 3.930282e-02 | 1.406 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.538903e-02 | 1.451 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 3.943428e-02 | 1.404 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.859904e-02 | 1.413 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.859904e-02 | 1.413 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 3.705652e-02 | 1.431 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.840445e-02 | 1.416 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 3.816319e-02 | 1.418 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.319287e-02 | 1.479 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.869375e-02 | 1.412 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.816319e-02 | 1.418 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.427631e-02 | 1.465 | 0 | 0 |
| Depurination | R-HSA-73927 | 3.404205e-02 | 1.468 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.968835e-02 | 1.401 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 4.022604e-02 | 1.395 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.112533e-02 | 1.386 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 4.157124e-02 | 1.381 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.248772e-02 | 1.372 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.248772e-02 | 1.372 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.248772e-02 | 1.372 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.302979e-02 | 1.366 | 0 | 0 |
| Kinesins | R-HSA-983189 | 4.302979e-02 | 1.366 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 4.328406e-02 | 1.364 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 4.412783e-02 | 1.355 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 4.435515e-02 | 1.353 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 4.562943e-02 | 1.341 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 4.642668e-02 | 1.333 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.661998e-02 | 1.331 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.676375e-02 | 1.330 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.690058e-02 | 1.329 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 4.885588e-02 | 1.311 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 4.958519e-02 | 1.305 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 4.998698e-02 | 1.301 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 5.026642e-02 | 1.299 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.768383e-02 | 1.239 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 5.768383e-02 | 1.239 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 5.768383e-02 | 1.239 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.768383e-02 | 1.239 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 5.768383e-02 | 1.239 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 5.768383e-02 | 1.239 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 5.910266e-02 | 1.228 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 5.910266e-02 | 1.228 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 5.910266e-02 | 1.228 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 5.910266e-02 | 1.228 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 5.910266e-02 | 1.228 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 5.492298e-02 | 1.260 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 5.492298e-02 | 1.260 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 6.065515e-02 | 1.217 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 5.270680e-02 | 1.278 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 6.276814e-02 | 1.202 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 5.223196e-02 | 1.282 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 6.170930e-02 | 1.210 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 5.503958e-02 | 1.259 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.849545e-02 | 1.233 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.849545e-02 | 1.233 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.849545e-02 | 1.233 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 5.950912e-02 | 1.225 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 6.147822e-02 | 1.211 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 6.130654e-02 | 1.212 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 5.601901e-02 | 1.252 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.847304e-02 | 1.233 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.130654e-02 | 1.212 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 6.292234e-02 | 1.201 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 6.065515e-02 | 1.217 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 6.065515e-02 | 1.217 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.940231e-02 | 1.226 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.305719e-02 | 1.200 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 5.409567e-02 | 1.267 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.599994e-02 | 1.252 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.599994e-02 | 1.252 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 6.244296e-02 | 1.205 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.186017e-02 | 1.285 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 5.419748e-02 | 1.266 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 5.940231e-02 | 1.226 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 5.159924e-02 | 1.287 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 5.889756e-02 | 1.230 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 5.940231e-02 | 1.226 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 6.130654e-02 | 1.212 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 5.492735e-02 | 1.260 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.886498e-02 | 1.230 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 5.940231e-02 | 1.226 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 6.436970e-02 | 1.191 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 6.436970e-02 | 1.191 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 6.436970e-02 | 1.191 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 6.437193e-02 | 1.191 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 6.614112e-02 | 1.180 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 6.614112e-02 | 1.180 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 6.722576e-02 | 1.172 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.853077e-02 | 1.164 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.855264e-02 | 1.164 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 6.924421e-02 | 1.160 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 6.924421e-02 | 1.160 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 6.924421e-02 | 1.160 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 6.924421e-02 | 1.160 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.984102e-02 | 1.156 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 7.016891e-02 | 1.154 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 7.059121e-02 | 1.151 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 7.066057e-02 | 1.151 | 0 | 0 |
| Defective Base Excision Repair Associated with OGG1 | R-HSA-9656249 | 7.090166e-02 | 1.149 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 7.090166e-02 | 1.149 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 7.090166e-02 | 1.149 | 0 | 0 |
| Transport of glycerol from adipocytes to the liver by Aquaporins | R-HSA-432030 | 7.090166e-02 | 1.149 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 7.090166e-02 | 1.149 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.112068e-02 | 1.148 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 7.206311e-02 | 1.142 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.215378e-02 | 1.142 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 7.215378e-02 | 1.142 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 7.387001e-02 | 1.132 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 7.419060e-02 | 1.130 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 7.492208e-02 | 1.125 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 7.535523e-02 | 1.123 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 7.568390e-02 | 1.121 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 7.759810e-02 | 1.110 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 7.759810e-02 | 1.110 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 7.833703e-02 | 1.106 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 7.909143e-02 | 1.102 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 7.942595e-02 | 1.100 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 8.101186e-02 | 1.091 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 8.236297e-02 | 1.084 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 8.236297e-02 | 1.084 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 8.236297e-02 | 1.084 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 8.264104e-02 | 1.083 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 8.264104e-02 | 1.083 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 8.264104e-02 | 1.083 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 8.264104e-02 | 1.083 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 8.264104e-02 | 1.083 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 8.264104e-02 | 1.083 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 8.466913e-02 | 1.072 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 8.519904e-02 | 1.070 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.542636e-02 | 1.068 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 8.542636e-02 | 1.068 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 8.542636e-02 | 1.068 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 8.542636e-02 | 1.068 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 8.588038e-02 | 1.066 | 1 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.149457e-01 | 0.940 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.149457e-01 | 0.940 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.149457e-01 | 0.940 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.149457e-01 | 0.940 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.149457e-01 | 0.940 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.149457e-01 | 0.940 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.149457e-01 | 0.940 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.149457e-01 | 0.940 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 1.149457e-01 | 0.940 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.149457e-01 | 0.940 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.113956e-01 | 0.953 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 9.862531e-02 | 1.006 | 1 | 1 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 9.862531e-02 | 1.006 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 8.772346e-02 | 1.057 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 8.772346e-02 | 1.057 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.721408e-02 | 1.059 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 1.010091e-01 | 0.996 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 9.339763e-02 | 1.030 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 1.052530e-01 | 0.978 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 8.731271e-02 | 1.059 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 1.018982e-01 | 0.992 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.033686e-01 | 0.986 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.033686e-01 | 0.986 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 8.916007e-02 | 1.050 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.014316e-01 | 0.994 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 8.721408e-02 | 1.059 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.113956e-01 | 0.953 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.034090e-01 | 0.985 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 8.906290e-02 | 1.050 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.058733e-01 | 0.975 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.018982e-01 | 0.992 | 0 | 0 |
| S Phase | R-HSA-69242 | 9.541524e-02 | 1.020 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 9.862531e-02 | 1.006 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 9.862531e-02 | 1.006 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 9.587737e-02 | 1.018 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.110631e-01 | 0.954 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.926185e-02 | 1.003 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 1.034090e-01 | 0.985 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 1.037552e-01 | 0.984 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 8.916007e-02 | 1.050 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 8.986354e-02 | 1.046 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.010091e-01 | 0.996 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 8.916007e-02 | 1.050 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.047929e-01 | 0.980 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.010091e-01 | 0.996 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 9.436676e-02 | 1.025 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 1.107240e-01 | 0.956 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 9.857092e-02 | 1.006 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.156766e-01 | 0.937 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.159189e-01 | 0.936 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.161206e-01 | 0.935 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.163437e-01 | 0.934 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.168468e-01 | 0.932 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.179178e-01 | 0.928 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.179178e-01 | 0.928 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.179714e-01 | 0.928 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.184263e-01 | 0.927 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.186517e-01 | 0.926 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.201180e-01 | 0.920 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.202596e-01 | 0.920 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 1.203636e-01 | 0.920 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 1.203636e-01 | 0.920 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.217054e-01 | 0.915 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.219934e-01 | 0.914 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.219934e-01 | 0.914 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.231007e-01 | 0.910 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 1.231007e-01 | 0.910 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.248861e-01 | 0.903 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.259677e-01 | 0.900 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.285420e-01 | 0.891 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.310595e-01 | 0.883 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.310595e-01 | 0.883 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.313744e-01 | 0.881 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.344942e-01 | 0.871 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.347165e-01 | 0.871 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.347165e-01 | 0.871 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.347165e-01 | 0.871 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.347165e-01 | 0.871 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.347165e-01 | 0.871 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.347165e-01 | 0.871 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.347165e-01 | 0.871 | 0 | 0 |
| Defective OGG1 Substrate Binding | R-HSA-9656255 | 1.347165e-01 | 0.871 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.347165e-01 | 0.871 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.347165e-01 | 0.871 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.347165e-01 | 0.871 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.347165e-01 | 0.871 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.347165e-01 | 0.871 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.347165e-01 | 0.871 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.347165e-01 | 0.871 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.347165e-01 | 0.871 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 1.347165e-01 | 0.871 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.347165e-01 | 0.871 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.347165e-01 | 0.871 | 0 | 0 |
| Defective OGG1 Localization | R-HSA-9657050 | 1.347165e-01 | 0.871 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.347165e-01 | 0.871 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.347165e-01 | 0.871 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.347165e-01 | 0.871 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.347165e-01 | 0.871 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 1.355010e-01 | 0.868 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.360866e-01 | 0.866 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.369211e-01 | 0.864 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.386434e-01 | 0.858 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.399448e-01 | 0.854 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.399448e-01 | 0.854 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.399448e-01 | 0.854 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.639871e-01 | 0.785 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.639871e-01 | 0.785 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.433591e-01 | 0.844 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.779132e-01 | 0.750 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.779132e-01 | 0.750 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.779132e-01 | 0.750 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 1.474678e-01 | 0.831 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 2.144445e-01 | 0.669 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.144445e-01 | 0.669 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 2.144445e-01 | 0.669 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 2.144445e-01 | 0.669 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.443837e-01 | 0.840 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.443837e-01 | 0.840 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.443837e-01 | 0.840 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 1.443837e-01 | 0.840 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.443837e-01 | 0.840 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.671189e-01 | 0.777 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.911511e-01 | 0.719 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.911511e-01 | 0.719 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.489228e-01 | 0.827 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 1.489228e-01 | 0.827 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.669100e-01 | 0.778 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.003267e-01 | 0.698 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 2.003267e-01 | 0.698 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 1.858008e-01 | 0.731 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.055210e-01 | 0.687 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 2.055210e-01 | 0.687 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.055210e-01 | 0.687 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.055210e-01 | 0.687 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.055210e-01 | 0.687 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 1.451999e-01 | 0.838 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.444186e-01 | 0.840 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.437028e-01 | 0.843 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.065063e-01 | 0.685 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.027721e-01 | 0.693 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.461241e-01 | 0.835 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.937292e-01 | 0.713 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.123314e-01 | 0.673 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.453121e-01 | 0.838 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.762291e-01 | 0.754 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.494785e-01 | 0.825 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.787233e-01 | 0.748 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.787233e-01 | 0.748 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 1.558627e-01 | 0.807 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.670532e-01 | 0.777 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 1.558627e-01 | 0.807 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.096709e-01 | 0.678 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.003267e-01 | 0.698 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.678191e-01 | 0.775 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 1.671189e-01 | 0.777 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 2.036596e-01 | 0.691 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.552371e-01 | 0.809 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.435558e-01 | 0.843 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.090934e-01 | 0.680 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.904918e-01 | 0.720 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.787233e-01 | 0.748 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.858008e-01 | 0.731 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.443837e-01 | 0.840 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 2.090934e-01 | 0.680 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 2.090934e-01 | 0.680 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.523008e-01 | 0.817 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.573190e-01 | 0.803 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 1.930300e-01 | 0.714 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.455990e-01 | 0.837 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.090934e-01 | 0.680 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.784420e-01 | 0.749 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 2.144445e-01 | 0.669 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 2.036596e-01 | 0.691 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 2.036596e-01 | 0.691 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.127493e-01 | 0.672 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 2.029814e-01 | 0.693 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.489379e-01 | 0.827 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 2.036596e-01 | 0.691 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 1.930300e-01 | 0.714 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 1.930300e-01 | 0.714 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 1.930300e-01 | 0.714 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 1.930300e-01 | 0.714 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.453121e-01 | 0.838 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.474678e-01 | 0.831 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 1.941150e-01 | 0.712 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.639871e-01 | 0.785 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 2.036596e-01 | 0.691 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.455990e-01 | 0.837 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.055210e-01 | 0.687 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 1.523008e-01 | 0.817 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.907014e-01 | 0.720 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 1.664049e-01 | 0.779 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.036596e-01 | 0.691 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.044842e-01 | 0.689 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.489228e-01 | 0.827 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.489228e-01 | 0.827 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.446136e-01 | 0.840 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.747842e-01 | 0.757 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 1.858008e-01 | 0.731 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.065063e-01 | 0.685 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 2.055210e-01 | 0.687 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.603855e-01 | 0.795 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 2.144445e-01 | 0.669 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 2.144445e-01 | 0.669 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.455990e-01 | 0.837 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 2.095121e-01 | 0.679 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.696379e-01 | 0.770 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 1.930300e-01 | 0.714 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.036596e-01 | 0.691 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.714161e-01 | 0.766 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.036596e-01 | 0.691 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 1.639871e-01 | 0.785 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.671189e-01 | 0.777 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.107282e-01 | 0.676 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 2.036596e-01 | 0.691 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 1.639871e-01 | 0.785 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.435558e-01 | 0.843 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.154055e-01 | 0.667 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.154055e-01 | 0.667 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 2.158815e-01 | 0.666 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 2.158815e-01 | 0.666 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 2.158815e-01 | 0.666 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 2.158815e-01 | 0.666 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 2.158815e-01 | 0.666 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 2.158815e-01 | 0.666 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.158815e-01 | 0.666 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.158815e-01 | 0.666 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.158815e-01 | 0.666 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.158815e-01 | 0.666 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.158815e-01 | 0.666 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 2.179651e-01 | 0.662 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.228261e-01 | 0.652 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 2.228261e-01 | 0.652 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.228261e-01 | 0.652 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.228909e-01 | 0.652 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.245422e-01 | 0.649 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.251672e-01 | 0.647 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.259901e-01 | 0.646 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.259901e-01 | 0.646 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.259901e-01 | 0.646 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.259901e-01 | 0.646 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.260781e-01 | 0.646 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.260781e-01 | 0.646 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 2.270369e-01 | 0.644 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.270369e-01 | 0.644 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 2.271506e-01 | 0.644 | 0 | 0 |
| Defective OGG1 Substrate Processing | R-HSA-9656256 | 2.512911e-01 | 0.600 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.512911e-01 | 0.600 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.512911e-01 | 0.600 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.512911e-01 | 0.600 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.512911e-01 | 0.600 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.512911e-01 | 0.600 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.512911e-01 | 0.600 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.512911e-01 | 0.600 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 3.521662e-01 | 0.453 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.521662e-01 | 0.453 | 0 | 0 |
| Mitochondrial transcription initiation | R-HSA-163282 | 3.521662e-01 | 0.453 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.521662e-01 | 0.453 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.521662e-01 | 0.453 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 3.521662e-01 | 0.453 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.521662e-01 | 0.453 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.521662e-01 | 0.453 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.521662e-01 | 0.453 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.521662e-01 | 0.453 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 3.521662e-01 | 0.453 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.521662e-01 | 0.453 | 0 | 0 |
| MPS IIID - Sanfilippo syndrome D | R-HSA-2206305 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.521662e-01 | 0.453 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.521662e-01 | 0.453 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 3.521662e-01 | 0.453 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.521662e-01 | 0.453 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.521662e-01 | 0.453 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 3.521662e-01 | 0.453 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 3.521662e-01 | 0.453 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.521662e-01 | 0.453 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.689710e-01 | 0.570 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 2.689710e-01 | 0.570 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.689710e-01 | 0.570 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.689710e-01 | 0.570 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.689710e-01 | 0.570 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 2.689710e-01 | 0.570 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 2.689710e-01 | 0.570 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 2.523683e-01 | 0.598 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 2.523683e-01 | 0.598 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 2.523683e-01 | 0.598 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 3.219924e-01 | 0.492 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 3.219924e-01 | 0.492 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 3.219924e-01 | 0.492 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.219924e-01 | 0.492 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 3.219924e-01 | 0.492 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 3.219924e-01 | 0.492 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 3.219924e-01 | 0.492 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.219924e-01 | 0.492 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 3.219924e-01 | 0.492 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.394552e-01 | 0.357 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.394552e-01 | 0.357 | 0 | 0 |
| Defective DHDDS causes RP59 | R-HSA-4755609 | 4.394552e-01 | 0.357 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 4.394552e-01 | 0.357 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 4.394552e-01 | 0.357 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 4.394552e-01 | 0.357 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.338035e-01 | 0.631 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 2.338035e-01 | 0.631 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.338035e-01 | 0.631 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 2.911443e-01 | 0.536 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.911443e-01 | 0.536 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 2.911443e-01 | 0.536 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 2.911443e-01 | 0.536 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 2.911443e-01 | 0.536 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 2.911443e-01 | 0.536 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.649260e-01 | 0.577 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 2.649260e-01 | 0.577 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 2.649260e-01 | 0.577 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.740008e-01 | 0.427 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 2.424306e-01 | 0.615 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 3.302850e-01 | 0.481 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.302850e-01 | 0.481 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 3.302850e-01 | 0.481 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 2.967448e-01 | 0.528 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 2.967448e-01 | 0.528 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.967448e-01 | 0.528 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.693263e-01 | 0.570 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 2.693263e-01 | 0.570 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.471231e-01 | 0.607 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.471231e-01 | 0.607 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.471231e-01 | 0.607 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.471231e-01 | 0.607 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.700396e-01 | 0.569 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 2.700396e-01 | 0.569 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.700396e-01 | 0.569 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.968232e-01 | 0.528 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 3.289911e-01 | 0.483 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.289911e-01 | 0.483 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 3.693611e-01 | 0.433 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 3.693611e-01 | 0.433 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 4.243072e-01 | 0.372 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 4.243072e-01 | 0.372 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 4.243072e-01 | 0.372 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 4.243072e-01 | 0.372 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 4.243072e-01 | 0.372 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 4.243072e-01 | 0.372 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 4.243072e-01 | 0.372 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 2.688315e-01 | 0.571 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.945099e-01 | 0.531 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.945099e-01 | 0.531 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 2.945099e-01 | 0.531 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 3.247475e-01 | 0.488 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.450840e-01 | 0.611 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.450840e-01 | 0.611 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.450840e-01 | 0.611 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.614130e-01 | 0.442 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.614130e-01 | 0.442 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 3.614130e-01 | 0.442 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.614130e-01 | 0.442 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 3.193925e-01 | 0.496 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.080020e-01 | 0.389 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.602746e-01 | 0.585 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 3.529317e-01 | 0.452 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 3.077063e-01 | 0.512 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.283748e-01 | 0.641 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.812162e-01 | 0.419 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.812162e-01 | 0.419 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.812162e-01 | 0.419 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 3.699164e-01 | 0.432 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.699164e-01 | 0.432 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 4.458945e-01 | 0.351 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.794265e-01 | 0.554 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 4.258801e-01 | 0.371 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 4.258801e-01 | 0.371 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.094514e-01 | 0.388 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 3.828322e-01 | 0.417 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 3.428318e-01 | 0.465 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.344997e-01 | 0.476 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.344997e-01 | 0.476 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 3.266434e-01 | 0.486 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.811278e-01 | 0.551 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.608681e-01 | 0.584 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.994512e-01 | 0.524 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 3.427845e-01 | 0.465 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 3.706443e-01 | 0.431 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.206949e-01 | 0.376 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.206949e-01 | 0.376 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 4.374986e-01 | 0.359 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 4.374986e-01 | 0.359 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 3.896759e-01 | 0.409 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.147117e-01 | 0.382 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 4.293266e-01 | 0.367 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.333128e-01 | 0.363 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.903494e-01 | 0.409 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.993786e-01 | 0.399 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 3.193925e-01 | 0.496 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.988059e-01 | 0.525 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 2.665374e-01 | 0.574 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 2.665374e-01 | 0.574 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 2.693263e-01 | 0.570 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 3.614130e-01 | 0.442 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.365021e-01 | 0.473 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.191071e-01 | 0.496 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.596046e-01 | 0.444 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 4.258801e-01 | 0.371 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.975514e-01 | 0.401 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.514585e-01 | 0.454 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 4.293266e-01 | 0.367 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 3.077063e-01 | 0.512 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.641641e-01 | 0.578 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 3.058519e-01 | 0.514 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 2.927660e-01 | 0.533 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 3.693611e-01 | 0.433 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 3.614130e-01 | 0.442 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.628777e-01 | 0.440 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 3.018178e-01 | 0.520 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.454563e-01 | 0.610 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 3.715595e-01 | 0.430 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.911443e-01 | 0.536 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 3.412341e-01 | 0.467 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.251212e-01 | 0.371 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 2.869344e-01 | 0.542 | 1 | 1 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 4.258801e-01 | 0.371 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 4.469247e-01 | 0.350 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.424306e-01 | 0.615 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.931225e-01 | 0.405 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 3.219924e-01 | 0.492 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 3.302850e-01 | 0.481 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 4.243072e-01 | 0.372 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.427845e-01 | 0.465 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 3.122379e-01 | 0.506 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.787157e-01 | 0.422 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.465863e-01 | 0.608 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.691063e-01 | 0.570 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 3.018178e-01 | 0.520 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 2.523683e-01 | 0.598 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.740008e-01 | 0.427 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 3.740008e-01 | 0.427 | 0 | 0 |
| PKA activation | R-HSA-163615 | 2.424306e-01 | 0.615 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 3.289911e-01 | 0.483 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 3.693611e-01 | 0.433 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 2.848105e-01 | 0.545 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.344997e-01 | 0.476 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.030315e-01 | 0.395 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 3.177154e-01 | 0.498 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.622602e-01 | 0.441 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.193925e-01 | 0.496 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 3.956388e-01 | 0.403 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.416612e-01 | 0.617 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 4.458945e-01 | 0.351 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 3.787483e-01 | 0.422 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.365021e-01 | 0.473 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.689710e-01 | 0.570 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.689710e-01 | 0.570 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.523683e-01 | 0.598 | 0 | 0 |
| Transcription from mitochondrial promoters | R-HSA-75944 | 4.394552e-01 | 0.357 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 3.693611e-01 | 0.433 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 4.243072e-01 | 0.372 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.937792e-01 | 0.405 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 4.458945e-01 | 0.351 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 4.458945e-01 | 0.351 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.741925e-01 | 0.562 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 3.919863e-01 | 0.407 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.781603e-01 | 0.422 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.596046e-01 | 0.444 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 2.967448e-01 | 0.528 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.523683e-01 | 0.598 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 4.265078e-01 | 0.370 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 2.338035e-01 | 0.631 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.911443e-01 | 0.536 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 4.060999e-01 | 0.391 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.106831e-01 | 0.508 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.219924e-01 | 0.492 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 3.289911e-01 | 0.483 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.085444e-01 | 0.389 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 3.365021e-01 | 0.473 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.459167e-01 | 0.351 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 2.324904e-01 | 0.634 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.689710e-01 | 0.570 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.953279e-01 | 0.403 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.289243e-01 | 0.368 | 1 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 3.596046e-01 | 0.444 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.762368e-01 | 0.559 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 2.351718e-01 | 0.629 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.927660e-01 | 0.533 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.945099e-01 | 0.531 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 3.289911e-01 | 0.483 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.512911e-01 | 0.600 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.512911e-01 | 0.600 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 3.521662e-01 | 0.453 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.521662e-01 | 0.453 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 3.521662e-01 | 0.453 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.689710e-01 | 0.570 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 2.523683e-01 | 0.598 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 2.523683e-01 | 0.598 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 4.394552e-01 | 0.357 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.394552e-01 | 0.357 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 4.394552e-01 | 0.357 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 4.394552e-01 | 0.357 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 3.302850e-01 | 0.481 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 2.700396e-01 | 0.569 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 3.289911e-01 | 0.483 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 4.243072e-01 | 0.372 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 3.247475e-01 | 0.488 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 3.193925e-01 | 0.496 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 4.080020e-01 | 0.389 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.077063e-01 | 0.512 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 3.011408e-01 | 0.521 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 3.412341e-01 | 0.467 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 4.094514e-01 | 0.388 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.402081e-01 | 0.468 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 4.218292e-01 | 0.375 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.420223e-01 | 0.355 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 3.607117e-01 | 0.443 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.258801e-01 | 0.371 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 3.950403e-01 | 0.403 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 2.911443e-01 | 0.536 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 2.700396e-01 | 0.569 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 2.552453e-01 | 0.593 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.869344e-01 | 0.542 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.177154e-01 | 0.498 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.429603e-01 | 0.614 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 4.184360e-01 | 0.378 | 1 | 0 |
| PECAM1 interactions | R-HSA-210990 | 3.302850e-01 | 0.481 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.665374e-01 | 0.574 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 2.945099e-01 | 0.531 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.549275e-01 | 0.342 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.251166e-01 | 0.488 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 3.781603e-01 | 0.422 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.868343e-01 | 0.542 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 2.338035e-01 | 0.631 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.424306e-01 | 0.615 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 3.693611e-01 | 0.433 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 4.243072e-01 | 0.372 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.365021e-01 | 0.473 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 3.121318e-01 | 0.506 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 4.087633e-01 | 0.389 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.832227e-01 | 0.548 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 3.529317e-01 | 0.452 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 3.247475e-01 | 0.488 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 3.219924e-01 | 0.492 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.693263e-01 | 0.570 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.744022e-01 | 0.562 | 0 | 0 |
| Diseases of Base Excision Repair | R-HSA-9605308 | 3.219924e-01 | 0.492 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 2.689710e-01 | 0.570 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 3.219924e-01 | 0.492 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 3.485523e-01 | 0.458 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 3.435867e-01 | 0.464 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 2.911443e-01 | 0.536 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.937792e-01 | 0.405 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.649260e-01 | 0.577 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.270109e-01 | 0.485 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 4.258801e-01 | 0.371 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 4.458945e-01 | 0.351 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 4.553810e-01 | 0.342 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 4.553810e-01 | 0.342 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.575295e-01 | 0.340 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.575295e-01 | 0.340 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 4.575295e-01 | 0.340 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.575295e-01 | 0.340 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.575295e-01 | 0.340 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 4.575295e-01 | 0.340 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 4.583675e-01 | 0.339 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.617288e-01 | 0.336 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.617288e-01 | 0.336 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.659120e-01 | 0.332 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.724262e-01 | 0.326 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.724262e-01 | 0.326 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 4.724262e-01 | 0.326 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 4.724262e-01 | 0.326 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 4.724262e-01 | 0.326 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 4.724262e-01 | 0.326 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 4.724262e-01 | 0.326 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 4.724262e-01 | 0.326 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.724262e-01 | 0.326 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 4.724262e-01 | 0.326 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.724262e-01 | 0.326 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 4.724262e-01 | 0.326 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 4.724262e-01 | 0.326 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.753534e-01 | 0.323 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 4.790075e-01 | 0.320 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 4.798194e-01 | 0.319 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 4.799727e-01 | 0.319 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 4.821011e-01 | 0.317 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 4.827802e-01 | 0.316 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 4.827802e-01 | 0.316 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 4.827802e-01 | 0.316 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 4.827802e-01 | 0.316 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.827802e-01 | 0.316 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 4.827802e-01 | 0.316 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 4.827802e-01 | 0.316 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 4.827802e-01 | 0.316 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 4.827802e-01 | 0.316 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 4.867395e-01 | 0.313 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 4.885640e-01 | 0.311 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.885640e-01 | 0.311 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 4.885640e-01 | 0.311 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.885640e-01 | 0.311 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 4.925338e-01 | 0.308 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.925338e-01 | 0.308 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 4.955593e-01 | 0.305 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 4.955593e-01 | 0.305 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.960673e-01 | 0.304 | 1 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.987930e-01 | 0.302 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.987930e-01 | 0.302 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 5.012181e-01 | 0.300 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 5.012181e-01 | 0.300 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.018930e-01 | 0.299 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.107060e-01 | 0.292 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.107060e-01 | 0.292 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.107060e-01 | 0.292 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 5.149872e-01 | 0.288 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 5.149872e-01 | 0.288 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 5.149872e-01 | 0.288 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 5.149872e-01 | 0.288 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 5.149872e-01 | 0.288 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 5.149872e-01 | 0.288 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 5.149872e-01 | 0.288 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.149872e-01 | 0.288 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 5.149872e-01 | 0.288 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 5.149872e-01 | 0.288 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 5.149872e-01 | 0.288 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 5.149872e-01 | 0.288 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 5.180340e-01 | 0.286 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 5.180340e-01 | 0.286 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 5.180340e-01 | 0.286 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 5.180340e-01 | 0.286 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 5.180340e-01 | 0.286 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 5.180340e-01 | 0.286 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.180340e-01 | 0.286 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 5.180340e-01 | 0.286 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 5.180340e-01 | 0.286 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 5.180340e-01 | 0.286 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 5.180340e-01 | 0.286 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 5.180340e-01 | 0.286 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.184513e-01 | 0.285 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.184513e-01 | 0.285 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 5.184513e-01 | 0.285 | 1 | 1 |
| p75NTR signals via NF-kB | R-HSA-193639 | 5.184513e-01 | 0.285 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 5.184513e-01 | 0.285 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 5.188436e-01 | 0.285 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 5.188436e-01 | 0.285 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 5.188436e-01 | 0.285 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 5.188436e-01 | 0.285 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 5.188436e-01 | 0.285 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.193057e-01 | 0.285 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 5.193057e-01 | 0.285 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 5.203539e-01 | 0.284 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.203539e-01 | 0.284 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.203539e-01 | 0.284 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.203539e-01 | 0.284 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.209053e-01 | 0.283 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.214619e-01 | 0.283 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.231197e-01 | 0.281 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.257531e-01 | 0.279 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 5.436007e-01 | 0.265 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 5.454573e-01 | 0.263 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 5.454573e-01 | 0.263 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 5.482501e-01 | 0.261 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 5.527461e-01 | 0.257 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 5.527461e-01 | 0.257 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.527461e-01 | 0.257 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.527461e-01 | 0.257 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 5.527461e-01 | 0.257 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 5.527461e-01 | 0.257 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 5.527461e-01 | 0.257 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.527691e-01 | 0.257 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.583495e-01 | 0.253 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.597740e-01 | 0.252 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 5.609339e-01 | 0.251 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 5.609339e-01 | 0.251 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 5.609339e-01 | 0.251 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 5.638530e-01 | 0.249 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 5.638976e-01 | 0.249 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 5.651355e-01 | 0.248 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 5.680598e-01 | 0.246 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.689353e-01 | 0.245 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 5.709118e-01 | 0.243 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 5.709118e-01 | 0.243 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.711312e-01 | 0.243 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 5.732309e-01 | 0.242 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.766868e-01 | 0.239 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.766868e-01 | 0.239 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 5.803453e-01 | 0.236 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 5.803453e-01 | 0.236 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 5.803453e-01 | 0.236 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 5.803453e-01 | 0.236 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 5.803453e-01 | 0.236 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.803453e-01 | 0.236 | 0 | 0 |
| Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate | R-HSA-2978092 | 5.803453e-01 | 0.236 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.803453e-01 | 0.236 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.803453e-01 | 0.236 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.813235e-01 | 0.236 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 5.833290e-01 | 0.234 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 5.855440e-01 | 0.232 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.855440e-01 | 0.232 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 5.855440e-01 | 0.232 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 5.855440e-01 | 0.232 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 5.855440e-01 | 0.232 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.855440e-01 | 0.232 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 5.895129e-01 | 0.230 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.908202e-01 | 0.229 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.908202e-01 | 0.229 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 5.956044e-01 | 0.225 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.006552e-01 | 0.221 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 6.006552e-01 | 0.221 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 6.010274e-01 | 0.221 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 6.010274e-01 | 0.221 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 6.010274e-01 | 0.221 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 6.010274e-01 | 0.221 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 6.010274e-01 | 0.221 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 6.010274e-01 | 0.221 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 6.040763e-01 | 0.219 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 6.115399e-01 | 0.214 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 6.147075e-01 | 0.211 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.167610e-01 | 0.210 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.167610e-01 | 0.210 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 6.167610e-01 | 0.210 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.167610e-01 | 0.210 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.167610e-01 | 0.210 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.167610e-01 | 0.210 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 6.167610e-01 | 0.210 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 6.185060e-01 | 0.209 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.233485e-01 | 0.205 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 6.328933e-01 | 0.199 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 6.368993e-01 | 0.196 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 6.368993e-01 | 0.196 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.368993e-01 | 0.196 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 6.368993e-01 | 0.196 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 6.368993e-01 | 0.196 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 6.368993e-01 | 0.196 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 6.368993e-01 | 0.196 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.368993e-01 | 0.196 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 6.368993e-01 | 0.196 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 6.368993e-01 | 0.196 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 6.368993e-01 | 0.196 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 6.368993e-01 | 0.196 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 6.379151e-01 | 0.195 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 6.379151e-01 | 0.195 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 6.382919e-01 | 0.195 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 6.382919e-01 | 0.195 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 6.382919e-01 | 0.195 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 6.382919e-01 | 0.195 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 6.382919e-01 | 0.195 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 6.382919e-01 | 0.195 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 6.382919e-01 | 0.195 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.387816e-01 | 0.195 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 6.419979e-01 | 0.192 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 6.425015e-01 | 0.192 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.425015e-01 | 0.192 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 6.448844e-01 | 0.191 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 6.448844e-01 | 0.191 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.463445e-01 | 0.190 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.463445e-01 | 0.190 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 6.463445e-01 | 0.190 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.463445e-01 | 0.190 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.463445e-01 | 0.190 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 6.501542e-01 | 0.187 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 6.526297e-01 | 0.185 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.535411e-01 | 0.185 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.554943e-01 | 0.183 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 6.554943e-01 | 0.183 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.557935e-01 | 0.183 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 6.557935e-01 | 0.183 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 6.574924e-01 | 0.182 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.614981e-01 | 0.179 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.641800e-01 | 0.178 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.658407e-01 | 0.177 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.658407e-01 | 0.177 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 6.727616e-01 | 0.172 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 6.727616e-01 | 0.172 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 6.727616e-01 | 0.172 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 6.727616e-01 | 0.172 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 6.734584e-01 | 0.172 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 6.734584e-01 | 0.172 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 6.734584e-01 | 0.172 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 6.734584e-01 | 0.172 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.739321e-01 | 0.171 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.742691e-01 | 0.171 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.742691e-01 | 0.171 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 6.742691e-01 | 0.171 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.747163e-01 | 0.171 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.819003e-01 | 0.166 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 6.858347e-01 | 0.164 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 6.858347e-01 | 0.164 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.858347e-01 | 0.164 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.858347e-01 | 0.164 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.858347e-01 | 0.164 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 6.858347e-01 | 0.164 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.858347e-01 | 0.164 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.858347e-01 | 0.164 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.858347e-01 | 0.164 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.858347e-01 | 0.164 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 6.858347e-01 | 0.164 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.858347e-01 | 0.164 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 6.858347e-01 | 0.164 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.858347e-01 | 0.164 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.858347e-01 | 0.164 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 6.858347e-01 | 0.164 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.858347e-01 | 0.164 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 6.858347e-01 | 0.164 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 6.858347e-01 | 0.164 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 6.858347e-01 | 0.164 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.858469e-01 | 0.164 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.858469e-01 | 0.164 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.921439e-01 | 0.160 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 6.926264e-01 | 0.160 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 6.979612e-01 | 0.156 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.981379e-01 | 0.156 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 6.999214e-01 | 0.155 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 7.005320e-01 | 0.155 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.005320e-01 | 0.155 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.005320e-01 | 0.155 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.005320e-01 | 0.155 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 7.022214e-01 | 0.154 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 7.022214e-01 | 0.154 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 7.022214e-01 | 0.154 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 7.045130e-01 | 0.152 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 7.045130e-01 | 0.152 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 7.045130e-01 | 0.152 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 7.045130e-01 | 0.152 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 7.045130e-01 | 0.152 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 7.045130e-01 | 0.152 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 7.045130e-01 | 0.152 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 7.045130e-01 | 0.152 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 7.045130e-01 | 0.152 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 7.055886e-01 | 0.151 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 7.061351e-01 | 0.151 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.061351e-01 | 0.151 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 7.062010e-01 | 0.151 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 7.073029e-01 | 0.150 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 7.089787e-01 | 0.149 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 7.097955e-01 | 0.149 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.110323e-01 | 0.148 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 7.110323e-01 | 0.148 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.110323e-01 | 0.148 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 7.127830e-01 | 0.147 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.163714e-01 | 0.145 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 7.186651e-01 | 0.143 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.191768e-01 | 0.143 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 7.191768e-01 | 0.143 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.210414e-01 | 0.142 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 7.237972e-01 | 0.140 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.237972e-01 | 0.140 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.251496e-01 | 0.140 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.251496e-01 | 0.140 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.256186e-01 | 0.139 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 7.281775e-01 | 0.138 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 7.281775e-01 | 0.138 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 7.281775e-01 | 0.138 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 7.281775e-01 | 0.138 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 7.281775e-01 | 0.138 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 7.281775e-01 | 0.138 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.281775e-01 | 0.138 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 7.281775e-01 | 0.138 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 7.281775e-01 | 0.138 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 7.281775e-01 | 0.138 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 7.281775e-01 | 0.138 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 7.281775e-01 | 0.138 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 7.281775e-01 | 0.138 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 7.281775e-01 | 0.138 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 7.281775e-01 | 0.138 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 7.281775e-01 | 0.138 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 7.281775e-01 | 0.138 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 7.286687e-01 | 0.137 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.329482e-01 | 0.135 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 7.336525e-01 | 0.135 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 7.336525e-01 | 0.135 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 7.336525e-01 | 0.135 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 7.336525e-01 | 0.135 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 7.336525e-01 | 0.135 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.370548e-01 | 0.133 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.395379e-01 | 0.131 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 7.439070e-01 | 0.128 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 7.439070e-01 | 0.128 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.441879e-01 | 0.128 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 7.441879e-01 | 0.128 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 7.441879e-01 | 0.128 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.455332e-01 | 0.128 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 7.481540e-01 | 0.126 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.488887e-01 | 0.126 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.534687e-01 | 0.123 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 7.546962e-01 | 0.122 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 7.591201e-01 | 0.120 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 7.603074e-01 | 0.119 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.603074e-01 | 0.119 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 7.603074e-01 | 0.119 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 7.603074e-01 | 0.119 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 7.603074e-01 | 0.119 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 7.603074e-01 | 0.119 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 7.603074e-01 | 0.119 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 7.603074e-01 | 0.119 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.603074e-01 | 0.119 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.631672e-01 | 0.117 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.634099e-01 | 0.117 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.634099e-01 | 0.117 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 7.648155e-01 | 0.116 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 7.648155e-01 | 0.116 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 7.648155e-01 | 0.116 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 7.648155e-01 | 0.116 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 7.648155e-01 | 0.116 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 7.648155e-01 | 0.116 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.648155e-01 | 0.116 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 7.648155e-01 | 0.116 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.648155e-01 | 0.116 | 0 | 0 |
| Cysteine formation from homocysteine | R-HSA-1614603 | 7.648155e-01 | 0.116 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.648155e-01 | 0.116 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.648155e-01 | 0.116 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 7.695893e-01 | 0.114 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.695893e-01 | 0.114 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 7.695893e-01 | 0.114 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.695893e-01 | 0.114 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 7.696505e-01 | 0.114 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.712708e-01 | 0.113 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 7.769586e-01 | 0.110 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 7.769586e-01 | 0.110 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.769586e-01 | 0.110 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 7.773193e-01 | 0.109 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 7.773193e-01 | 0.109 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 7.774535e-01 | 0.109 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 7.789012e-01 | 0.109 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 7.814870e-01 | 0.107 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.814870e-01 | 0.107 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.814870e-01 | 0.107 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 7.846179e-01 | 0.105 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 7.846179e-01 | 0.105 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 7.846179e-01 | 0.105 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 7.846179e-01 | 0.105 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 7.846179e-01 | 0.105 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 7.846179e-01 | 0.105 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 7.846179e-01 | 0.105 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.846179e-01 | 0.105 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.895096e-01 | 0.103 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 7.895096e-01 | 0.103 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 7.895096e-01 | 0.103 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 7.895096e-01 | 0.103 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 7.915352e-01 | 0.102 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 7.915352e-01 | 0.102 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 7.917264e-01 | 0.101 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.930846e-01 | 0.101 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 7.936424e-01 | 0.100 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.953809e-01 | 0.099 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 7.965170e-01 | 0.099 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 7.965170e-01 | 0.099 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.965170e-01 | 0.099 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.965170e-01 | 0.099 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 7.965170e-01 | 0.099 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.965170e-01 | 0.099 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 7.965170e-01 | 0.099 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 7.965170e-01 | 0.099 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.965170e-01 | 0.099 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.965170e-01 | 0.099 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.984489e-01 | 0.098 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.995809e-01 | 0.097 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.031057e-01 | 0.095 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 8.032095e-01 | 0.095 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 8.039895e-01 | 0.095 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 8.046963e-01 | 0.094 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 8.046963e-01 | 0.094 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 8.053704e-01 | 0.094 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.053704e-01 | 0.094 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 8.067317e-01 | 0.093 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 8.067317e-01 | 0.093 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 8.079762e-01 | 0.093 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 8.079762e-01 | 0.093 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 8.079762e-01 | 0.093 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.084342e-01 | 0.092 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.084342e-01 | 0.092 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 8.084342e-01 | 0.092 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 8.096158e-01 | 0.092 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.113300e-01 | 0.091 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.113300e-01 | 0.091 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.113300e-01 | 0.091 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 8.143303e-01 | 0.089 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.143303e-01 | 0.089 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.164600e-01 | 0.088 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.165529e-01 | 0.088 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 8.239469e-01 | 0.084 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 8.239469e-01 | 0.084 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 8.239469e-01 | 0.084 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 8.239469e-01 | 0.084 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 8.239469e-01 | 0.084 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 8.239469e-01 | 0.084 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.250558e-01 | 0.084 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.250558e-01 | 0.084 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 8.267992e-01 | 0.083 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.267992e-01 | 0.083 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 8.267992e-01 | 0.083 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.267992e-01 | 0.083 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.267992e-01 | 0.083 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.268630e-01 | 0.083 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 8.291698e-01 | 0.081 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.291698e-01 | 0.081 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 8.354730e-01 | 0.078 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 8.354730e-01 | 0.078 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.393663e-01 | 0.076 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.398330e-01 | 0.076 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.408184e-01 | 0.075 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 8.408184e-01 | 0.075 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.408184e-01 | 0.075 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 8.430091e-01 | 0.074 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 8.430091e-01 | 0.074 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 8.430091e-01 | 0.074 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 8.430091e-01 | 0.074 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 8.449700e-01 | 0.073 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 8.449700e-01 | 0.073 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 8.449700e-01 | 0.073 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 8.451101e-01 | 0.073 | 0 | 0 |
| Immune System | R-HSA-168256 | 8.460348e-01 | 0.073 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.462740e-01 | 0.072 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 8.476806e-01 | 0.072 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 8.476806e-01 | 0.072 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 8.476806e-01 | 0.072 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.476806e-01 | 0.072 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.476806e-01 | 0.072 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 8.476806e-01 | 0.072 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 8.476806e-01 | 0.072 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 8.476806e-01 | 0.072 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.476806e-01 | 0.072 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.476806e-01 | 0.072 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.476806e-01 | 0.072 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 8.476806e-01 | 0.072 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 8.476806e-01 | 0.072 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.476806e-01 | 0.072 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 8.476806e-01 | 0.072 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.499332e-01 | 0.071 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.510109e-01 | 0.070 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 8.536398e-01 | 0.069 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 8.547658e-01 | 0.068 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 8.553361e-01 | 0.068 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.558918e-01 | 0.068 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 8.613908e-01 | 0.065 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 8.613908e-01 | 0.065 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.642736e-01 | 0.063 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 8.682159e-01 | 0.061 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.682159e-01 | 0.061 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 8.682159e-01 | 0.061 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 8.682159e-01 | 0.061 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 8.682159e-01 | 0.061 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.682159e-01 | 0.061 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 8.682159e-01 | 0.061 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 8.682159e-01 | 0.061 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.682159e-01 | 0.061 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.682159e-01 | 0.061 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.686817e-01 | 0.061 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 8.686817e-01 | 0.061 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.686817e-01 | 0.061 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 8.695717e-01 | 0.061 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 8.762032e-01 | 0.057 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 8.762032e-01 | 0.057 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 8.762032e-01 | 0.057 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 8.762032e-01 | 0.057 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 8.762032e-01 | 0.057 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.774651e-01 | 0.057 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 8.789688e-01 | 0.056 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 8.805358e-01 | 0.055 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.809280e-01 | 0.055 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 8.859838e-01 | 0.053 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.859838e-01 | 0.053 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 8.859838e-01 | 0.053 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.859838e-01 | 0.053 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 8.859838e-01 | 0.053 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.859838e-01 | 0.053 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.892552e-01 | 0.051 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.892552e-01 | 0.051 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 8.895421e-01 | 0.051 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 8.895421e-01 | 0.051 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 8.895421e-01 | 0.051 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 8.895421e-01 | 0.051 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 8.895421e-01 | 0.051 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 8.895421e-01 | 0.051 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 8.895421e-01 | 0.051 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 8.895421e-01 | 0.051 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.895792e-01 | 0.051 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.895792e-01 | 0.051 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.916213e-01 | 0.050 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.921465e-01 | 0.050 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 8.931307e-01 | 0.049 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 8.946117e-01 | 0.048 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.987681e-01 | 0.046 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 8.996887e-01 | 0.046 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 9.013569e-01 | 0.045 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 9.013569e-01 | 0.045 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 9.013569e-01 | 0.045 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 9.013569e-01 | 0.045 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 9.013569e-01 | 0.045 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 9.013569e-01 | 0.045 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.013569e-01 | 0.045 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 9.013569e-01 | 0.045 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 9.013569e-01 | 0.045 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 9.013569e-01 | 0.045 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 9.013569e-01 | 0.045 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 9.013569e-01 | 0.045 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 9.013569e-01 | 0.045 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 9.015357e-01 | 0.045 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.015357e-01 | 0.045 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.024070e-01 | 0.045 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.057918e-01 | 0.043 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.064939e-01 | 0.043 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.075529e-01 | 0.042 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 9.075529e-01 | 0.042 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.123041e-01 | 0.040 | 0 | 0 |
| Free fatty acid receptors | R-HSA-444209 | 9.123041e-01 | 0.040 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 9.123041e-01 | 0.040 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.123041e-01 | 0.040 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.123041e-01 | 0.040 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 9.146581e-01 | 0.039 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 9.146581e-01 | 0.039 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.146581e-01 | 0.039 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 9.146581e-01 | 0.039 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.146581e-01 | 0.039 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 9.146581e-01 | 0.039 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 9.146581e-01 | 0.039 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 9.146581e-01 | 0.039 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.155740e-01 | 0.038 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.156540e-01 | 0.038 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.156540e-01 | 0.038 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.156540e-01 | 0.038 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 9.208650e-01 | 0.036 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.219596e-01 | 0.035 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.219596e-01 | 0.035 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.219596e-01 | 0.035 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.219596e-01 | 0.035 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.219596e-01 | 0.035 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.219596e-01 | 0.035 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.219596e-01 | 0.035 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 9.231146e-01 | 0.035 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.231146e-01 | 0.035 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.231146e-01 | 0.035 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.231146e-01 | 0.035 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.231146e-01 | 0.035 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.235605e-01 | 0.035 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 9.261663e-01 | 0.033 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 9.261663e-01 | 0.033 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 9.261663e-01 | 0.033 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 9.261663e-01 | 0.033 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 9.261663e-01 | 0.033 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 9.261663e-01 | 0.033 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 9.261663e-01 | 0.033 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 9.261663e-01 | 0.033 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 9.261663e-01 | 0.033 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.261663e-01 | 0.033 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.299765e-01 | 0.032 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.299765e-01 | 0.032 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.300328e-01 | 0.032 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.306065e-01 | 0.031 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.306065e-01 | 0.031 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.306065e-01 | 0.031 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.306065e-01 | 0.031 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.306065e-01 | 0.031 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.336471e-01 | 0.030 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.336471e-01 | 0.030 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.351815e-01 | 0.029 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 9.351815e-01 | 0.029 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 9.351815e-01 | 0.029 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.361233e-01 | 0.029 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.361233e-01 | 0.029 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 9.361233e-01 | 0.029 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 9.361233e-01 | 0.029 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 9.361233e-01 | 0.029 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.361233e-01 | 0.029 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.361233e-01 | 0.029 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 9.362800e-01 | 0.029 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.362800e-01 | 0.029 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.380192e-01 | 0.028 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.380192e-01 | 0.028 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 9.383412e-01 | 0.028 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.383412e-01 | 0.028 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.383412e-01 | 0.028 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.383412e-01 | 0.028 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.383412e-01 | 0.028 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.383412e-01 | 0.028 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.392254e-01 | 0.027 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.416106e-01 | 0.026 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.420636e-01 | 0.026 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.443781e-01 | 0.025 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 9.447380e-01 | 0.025 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.447380e-01 | 0.025 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 9.447380e-01 | 0.025 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.447380e-01 | 0.025 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.447380e-01 | 0.025 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.452523e-01 | 0.024 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.473888e-01 | 0.023 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.474440e-01 | 0.023 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 9.474440e-01 | 0.023 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 9.474440e-01 | 0.023 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.474440e-01 | 0.023 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.480989e-01 | 0.023 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 9.514213e-01 | 0.022 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.514213e-01 | 0.022 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.514213e-01 | 0.022 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.514213e-01 | 0.022 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 9.521913e-01 | 0.021 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.521913e-01 | 0.021 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.521913e-01 | 0.021 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 9.521913e-01 | 0.021 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 9.521913e-01 | 0.021 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.521913e-01 | 0.021 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.521913e-01 | 0.021 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.521913e-01 | 0.021 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 9.521913e-01 | 0.021 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.522169e-01 | 0.021 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.522169e-01 | 0.021 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.527308e-01 | 0.021 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.527308e-01 | 0.021 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.527308e-01 | 0.021 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.529936e-01 | 0.021 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.548134e-01 | 0.020 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.563792e-01 | 0.019 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.566547e-01 | 0.019 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.566547e-01 | 0.019 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.569227e-01 | 0.019 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.575513e-01 | 0.019 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.580550e-01 | 0.019 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.584887e-01 | 0.018 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.586397e-01 | 0.018 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.586397e-01 | 0.018 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.586397e-01 | 0.018 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.586397e-01 | 0.018 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 9.586397e-01 | 0.018 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 9.586397e-01 | 0.018 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.586397e-01 | 0.018 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 9.586397e-01 | 0.018 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.588711e-01 | 0.018 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.593569e-01 | 0.018 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.612032e-01 | 0.017 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.618462e-01 | 0.017 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.618462e-01 | 0.017 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.619636e-01 | 0.017 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.634841e-01 | 0.016 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.642187e-01 | 0.016 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.642187e-01 | 0.016 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.642187e-01 | 0.016 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.642187e-01 | 0.016 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.661875e-01 | 0.015 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.661875e-01 | 0.015 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.668013e-01 | 0.015 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.674725e-01 | 0.014 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.690454e-01 | 0.014 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.690454e-01 | 0.014 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.690454e-01 | 0.014 | 0 | 0 |
| Methionine salvage pathway | R-HSA-1237112 | 9.690454e-01 | 0.014 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.690454e-01 | 0.014 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.690454e-01 | 0.014 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.692560e-01 | 0.014 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.692885e-01 | 0.014 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.700687e-01 | 0.013 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 9.700687e-01 | 0.013 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.700687e-01 | 0.013 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.700687e-01 | 0.013 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.704728e-01 | 0.013 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.708568e-01 | 0.013 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.708568e-01 | 0.013 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.724729e-01 | 0.012 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.732213e-01 | 0.012 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.732213e-01 | 0.012 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 9.732213e-01 | 0.012 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.732213e-01 | 0.012 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.732213e-01 | 0.012 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 9.753424e-01 | 0.011 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.753424e-01 | 0.011 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.754656e-01 | 0.011 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.760964e-01 | 0.011 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.765823e-01 | 0.010 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.768341e-01 | 0.010 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.768341e-01 | 0.010 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.768341e-01 | 0.010 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.779261e-01 | 0.010 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.786320e-01 | 0.009 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.793017e-01 | 0.009 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.793017e-01 | 0.009 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.796176e-01 | 0.009 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.799596e-01 | 0.009 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 9.799596e-01 | 0.009 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.799596e-01 | 0.009 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.799596e-01 | 0.009 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.799596e-01 | 0.009 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.800090e-01 | 0.009 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.802505e-01 | 0.009 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.806087e-01 | 0.009 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.817138e-01 | 0.008 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.817138e-01 | 0.008 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.817138e-01 | 0.008 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.823401e-01 | 0.008 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.823401e-01 | 0.008 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 9.826636e-01 | 0.008 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.826636e-01 | 0.008 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.826636e-01 | 0.008 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.826636e-01 | 0.008 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.826636e-01 | 0.008 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.838520e-01 | 0.007 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.838520e-01 | 0.007 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.844231e-01 | 0.007 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.848283e-01 | 0.007 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.850029e-01 | 0.007 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.850029e-01 | 0.007 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.850029e-01 | 0.007 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.850029e-01 | 0.007 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.850301e-01 | 0.007 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.853696e-01 | 0.006 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.857462e-01 | 0.006 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 9.858023e-01 | 0.006 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.870266e-01 | 0.006 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.870266e-01 | 0.006 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.872176e-01 | 0.006 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.872176e-01 | 0.006 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.874137e-01 | 0.006 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.874234e-01 | 0.005 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.874234e-01 | 0.005 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.874536e-01 | 0.005 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.887774e-01 | 0.005 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.887774e-01 | 0.005 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.888712e-01 | 0.005 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.889077e-01 | 0.005 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.889077e-01 | 0.005 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.889077e-01 | 0.005 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.889077e-01 | 0.005 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.896553e-01 | 0.005 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.899748e-01 | 0.004 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.902205e-01 | 0.004 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.902205e-01 | 0.004 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.902919e-01 | 0.004 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.902919e-01 | 0.004 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.904361e-01 | 0.004 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.910697e-01 | 0.004 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.912666e-01 | 0.004 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.913810e-01 | 0.004 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.916022e-01 | 0.004 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.916022e-01 | 0.004 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.916022e-01 | 0.004 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.916022e-01 | 0.004 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.920423e-01 | 0.003 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.923375e-01 | 0.003 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.924066e-01 | 0.003 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.927345e-01 | 0.003 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.927357e-01 | 0.003 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.929122e-01 | 0.003 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.934980e-01 | 0.003 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.935521e-01 | 0.003 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.936734e-01 | 0.003 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.937162e-01 | 0.003 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.937162e-01 | 0.003 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.937162e-01 | 0.003 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 9.937162e-01 | 0.003 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.937162e-01 | 0.003 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.939266e-01 | 0.003 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.939570e-01 | 0.003 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.941786e-01 | 0.003 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.941786e-01 | 0.003 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.944931e-01 | 0.002 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.945058e-01 | 0.002 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.945252e-01 | 0.002 | 0 | 0 |
| Mucopolysaccharidoses | R-HSA-2206281 | 9.945645e-01 | 0.002 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.950043e-01 | 0.002 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.952983e-01 | 0.002 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.952983e-01 | 0.002 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.959330e-01 | 0.002 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.959330e-01 | 0.002 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.959892e-01 | 0.002 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.959892e-01 | 0.002 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.964731e-01 | 0.002 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.964821e-01 | 0.002 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.964821e-01 | 0.002 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.964914e-01 | 0.002 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.967460e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.968758e-01 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.968836e-01 | 0.001 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.968836e-01 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.968994e-01 | 0.001 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.968994e-01 | 0.001 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.969571e-01 | 0.001 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.969571e-01 | 0.001 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.969571e-01 | 0.001 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.969571e-01 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.972329e-01 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.972329e-01 | 0.001 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.972750e-01 | 0.001 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.972750e-01 | 0.001 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.973680e-01 | 0.001 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.973680e-01 | 0.001 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.973680e-01 | 0.001 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.977234e-01 | 0.001 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.977234e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.977657e-01 | 0.001 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.978967e-01 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.979378e-01 | 0.001 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.980308e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.981529e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.981734e-01 | 0.001 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.982968e-01 | 0.001 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.982968e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.984073e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.984073e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.984349e-01 | 0.001 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.984904e-01 | 0.001 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.986135e-01 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.986536e-01 | 0.001 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.986536e-01 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.986645e-01 | 0.001 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.987258e-01 | 0.001 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.987258e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.988072e-01 | 0.001 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.990468e-01 | 0.000 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.990468e-01 | 0.000 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.990647e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.991567e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.991721e-01 | 0.000 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.991755e-01 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.991959e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.992674e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.993778e-01 | 0.000 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.993833e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.994229e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.994268e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.994318e-01 | 0.000 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.994666e-01 | 0.000 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.994666e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.994666e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.994932e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.994956e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.995020e-01 | 0.000 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.995387e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.995387e-01 | 0.000 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.995610e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.996178e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.996502e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.996502e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.996652e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.996652e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.996684e-01 | 0.000 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 9.997419e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.997419e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.997591e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.997753e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.998375e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998449e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.998552e-01 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.998556e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.998622e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.998682e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.998682e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.998864e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.998864e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998915e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.998920e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.998920e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.998992e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999038e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999066e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.999066e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999134e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999303e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.999396e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.999396e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999406e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.999478e-01 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.999478e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999527e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999656e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.999662e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999746e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.999747e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999752e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999766e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999771e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999776e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999801e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.999811e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.999812e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.999878e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999878e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999884e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.999894e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999911e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999921e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999949e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.999949e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999967e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999984e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999990e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999991e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999996e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999998e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999998e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.110223e-16 | 15.955 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.110223e-16 | 15.955 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.110223e-16 | 15.955 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 2.220446e-16 | 15.654 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 2.220446e-16 | 15.654 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 4.440892e-16 | 15.353 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 5.551115e-16 | 15.256 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.110223e-15 | 14.955 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.887379e-15 | 14.724 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 2.331468e-15 | 14.632 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 5.884182e-15 | 14.230 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.661338e-15 | 14.176 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 7.660539e-15 | 14.116 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 7.660539e-15 | 14.116 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.498801e-14 | 13.824 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 3.042011e-14 | 13.517 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 3.597123e-14 | 13.444 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 3.452794e-14 | 13.462 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.319567e-14 | 13.479 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.419975e-13 | 12.848 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.154943e-13 | 12.667 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.856915e-13 | 12.414 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 4.146683e-13 | 12.382 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.202194e-13 | 12.377 | 0 | 0 |
| M Phase | R-HSA-68886 | 9.878764e-13 | 12.005 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.904921e-12 | 11.720 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 5.172085e-12 | 11.286 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 6.326828e-12 | 11.199 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 2.441580e-11 | 10.612 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 2.615164e-11 | 10.583 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 9.907319e-11 | 10.004 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.616388e-10 | 9.791 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.155470e-10 | 9.666 | 1 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.693931e-10 | 9.570 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.512080e-10 | 9.346 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 6.560898e-10 | 9.183 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 6.907603e-10 | 9.161 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 9.081571e-10 | 9.042 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.041347e-09 | 8.982 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 1.303851e-09 | 8.885 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.019550e-09 | 8.695 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.540633e-09 | 8.451 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.735937e-09 | 8.428 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.792314e-09 | 8.421 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.945134e-09 | 8.404 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.872705e-09 | 8.231 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 8.000980e-09 | 8.097 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.010276e-08 | 7.996 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.079370e-08 | 7.967 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.301699e-08 | 7.885 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.545700e-08 | 7.811 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.850937e-08 | 7.733 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.850937e-08 | 7.733 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 2.295715e-08 | 7.639 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.006636e-08 | 7.522 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.644241e-08 | 7.438 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.969498e-08 | 7.304 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 5.551588e-08 | 7.256 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 5.884713e-08 | 7.230 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.780034e-08 | 7.169 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.029694e-07 | 6.987 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.048085e-07 | 6.980 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.157003e-07 | 6.937 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.187028e-07 | 6.926 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 1.236288e-07 | 6.908 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.391333e-07 | 6.857 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.710831e-07 | 6.767 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.164328e-07 | 6.665 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.152224e-07 | 6.667 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.359857e-07 | 6.627 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.332970e-07 | 6.632 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.776386e-07 | 6.557 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 3.746131e-07 | 6.426 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.874046e-07 | 6.412 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.874046e-07 | 6.412 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 3.708966e-07 | 6.431 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 4.457287e-07 | 6.351 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.303955e-07 | 6.275 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 6.418919e-07 | 6.193 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 6.314066e-07 | 6.200 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 6.928707e-07 | 6.159 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 7.778478e-07 | 6.109 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 8.711356e-07 | 6.060 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 8.436643e-07 | 6.074 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.331251e-07 | 6.030 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.050823e-06 | 5.978 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.230694e-06 | 5.910 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.597875e-06 | 5.796 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.580832e-06 | 5.801 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.824248e-06 | 5.739 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 2.253761e-06 | 5.647 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.359368e-06 | 5.627 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.359368e-06 | 5.627 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.972360e-06 | 5.527 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.328964e-06 | 5.478 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 3.884800e-06 | 5.411 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.943676e-06 | 5.404 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.497895e-06 | 5.347 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 4.786553e-06 | 5.320 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 4.750818e-06 | 5.323 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 4.821755e-06 | 5.317 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 5.150224e-06 | 5.288 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.523996e-06 | 5.258 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 5.689418e-06 | 5.245 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 5.754763e-06 | 5.240 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 5.754763e-06 | 5.240 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 6.205383e-06 | 5.207 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.852564e-06 | 5.164 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 7.484492e-06 | 5.126 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.095385e-06 | 5.092 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 7.989443e-06 | 5.097 | 0 | 0 |
| Depurination | R-HSA-73927 | 7.666261e-06 | 5.115 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.984045e-06 | 5.098 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.984045e-06 | 5.098 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 8.398416e-06 | 5.076 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.957439e-06 | 5.048 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 9.716193e-06 | 5.013 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.036520e-05 | 4.984 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.071992e-05 | 4.970 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.072407e-05 | 4.970 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.324280e-05 | 4.878 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.271025e-05 | 4.896 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.355261e-05 | 4.868 | 1 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.376958e-05 | 4.861 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.551029e-05 | 4.809 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.726207e-05 | 4.763 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.810685e-05 | 4.742 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.862749e-05 | 4.730 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.862749e-05 | 4.730 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 1.726207e-05 | 4.763 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.178483e-05 | 4.662 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.178483e-05 | 4.662 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.178483e-05 | 4.662 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.178483e-05 | 4.662 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.178700e-05 | 4.662 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 2.207930e-05 | 4.656 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 3.192150e-05 | 4.496 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.261384e-05 | 4.487 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.924310e-05 | 4.406 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.642628e-05 | 4.439 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.675490e-05 | 4.435 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.924310e-05 | 4.406 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 3.924310e-05 | 4.406 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 4.230094e-05 | 4.374 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.774333e-05 | 4.321 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 4.774333e-05 | 4.321 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 4.800893e-05 | 4.319 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 6.218092e-05 | 4.206 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.275885e-05 | 4.202 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 6.537432e-05 | 4.185 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 6.566397e-05 | 4.183 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 7.697016e-05 | 4.114 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 7.697016e-05 | 4.114 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 7.231300e-05 | 4.141 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.337074e-05 | 4.134 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.018548e-04 | 3.992 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.141322e-04 | 3.943 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.223310e-04 | 3.912 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.289074e-04 | 3.890 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.314977e-04 | 3.881 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.314977e-04 | 3.881 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.341300e-04 | 3.872 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.379345e-04 | 3.860 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.429949e-04 | 3.845 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.744620e-04 | 3.758 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.744620e-04 | 3.758 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.703934e-04 | 3.769 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.619241e-04 | 3.791 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.829202e-04 | 3.738 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.829202e-04 | 3.738 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.835169e-04 | 3.736 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.929296e-04 | 3.715 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.958736e-04 | 3.708 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.029125e-04 | 3.693 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 2.029125e-04 | 3.693 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.042448e-04 | 3.690 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.230724e-04 | 3.652 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.319192e-04 | 3.635 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.356288e-04 | 3.628 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.665646e-04 | 3.574 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.773412e-04 | 3.557 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.870618e-04 | 3.542 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.870618e-04 | 3.542 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.249474e-04 | 3.488 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.906101e-04 | 3.537 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.476660e-04 | 3.459 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.522570e-04 | 3.453 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.634866e-04 | 3.440 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.634866e-04 | 3.440 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 4.199131e-04 | 3.377 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 5.168415e-04 | 3.287 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 5.353443e-04 | 3.271 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 6.052206e-04 | 3.218 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.509228e-04 | 3.186 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.631346e-04 | 3.178 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 6.739405e-04 | 3.171 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 6.970636e-04 | 3.157 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.991510e-04 | 3.155 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 8.310233e-04 | 3.080 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 8.377997e-04 | 3.077 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 8.653469e-04 | 3.063 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 8.653469e-04 | 3.063 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.046335e-03 | 2.980 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.101382e-03 | 2.958 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.136019e-03 | 2.945 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.136019e-03 | 2.945 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.219237e-03 | 2.914 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.136019e-03 | 2.945 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.296582e-03 | 2.887 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.337970e-03 | 2.874 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.344857e-03 | 2.871 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.451317e-03 | 2.838 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.452923e-03 | 2.838 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.544747e-03 | 2.811 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.575741e-03 | 2.803 | 0 | 0 |
| Translation | R-HSA-72766 | 1.579744e-03 | 2.801 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.588822e-03 | 2.799 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.594117e-03 | 2.797 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.615303e-03 | 2.792 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.620342e-03 | 2.790 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.756540e-03 | 2.755 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.768266e-03 | 2.752 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.851599e-03 | 2.732 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.851599e-03 | 2.732 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.851599e-03 | 2.732 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.965940e-03 | 2.706 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.000733e-03 | 2.699 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.113325e-03 | 2.675 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.113325e-03 | 2.675 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.377327e-03 | 2.624 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.423713e-03 | 2.616 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 2.684752e-03 | 2.571 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.684752e-03 | 2.571 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.605286e-03 | 2.584 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.901175e-03 | 2.537 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.901175e-03 | 2.537 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.635770e-03 | 2.579 | 1 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.633068e-03 | 2.580 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.616815e-03 | 2.582 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.773475e-03 | 2.557 | 1 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.806302e-03 | 2.552 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.073538e-03 | 2.512 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.124505e-03 | 2.505 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 3.378805e-03 | 2.471 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.388754e-03 | 2.470 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.440165e-03 | 2.463 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.440545e-03 | 2.463 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.542627e-03 | 2.451 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.573110e-03 | 2.447 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.623234e-03 | 2.441 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 3.703770e-03 | 2.431 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 3.729697e-03 | 2.428 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.740174e-03 | 2.427 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.740174e-03 | 2.427 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.984770e-03 | 2.400 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.082383e-03 | 2.389 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 4.082383e-03 | 2.389 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.203373e-03 | 2.376 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.308036e-03 | 2.366 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 4.341275e-03 | 2.362 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 4.584056e-03 | 2.339 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 4.927732e-03 | 2.307 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.974793e-03 | 2.303 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 5.100278e-03 | 2.292 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 5.425592e-03 | 2.266 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.915857e-03 | 2.228 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 5.915857e-03 | 2.228 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 6.414847e-03 | 2.193 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.910506e-03 | 2.160 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 7.151330e-03 | 2.146 | 1 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 7.447088e-03 | 2.128 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.371891e-03 | 2.077 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 8.371891e-03 | 2.077 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 8.649672e-03 | 2.063 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.011841e-02 | 1.995 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 9.252415e-03 | 2.034 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.774340e-03 | 2.057 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.002013e-02 | 1.999 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 8.807214e-03 | 2.055 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 9.180160e-03 | 2.037 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.011841e-02 | 1.995 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 9.736468e-03 | 2.012 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 9.116146e-03 | 2.040 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 8.529133e-03 | 2.069 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.098268e-02 | 1.959 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 1.098268e-02 | 1.959 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.098268e-02 | 1.959 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.116950e-02 | 1.952 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.194949e-02 | 1.923 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.209523e-02 | 1.917 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.285488e-02 | 1.891 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.301276e-02 | 1.886 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.301276e-02 | 1.886 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.450507e-02 | 1.838 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.456392e-02 | 1.837 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.521623e-02 | 1.818 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.521623e-02 | 1.818 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.553061e-02 | 1.809 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.553061e-02 | 1.809 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.566517e-02 | 1.805 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.566517e-02 | 1.805 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.568525e-02 | 1.805 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.612692e-02 | 1.792 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 1.612927e-02 | 1.792 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.628883e-02 | 1.788 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.643728e-02 | 1.784 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.656321e-02 | 1.781 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.657820e-02 | 1.780 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.682198e-02 | 1.774 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.721533e-02 | 1.764 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.754168e-02 | 1.756 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.808896e-02 | 1.743 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.808896e-02 | 1.743 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.862142e-02 | 1.730 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.862142e-02 | 1.730 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.862142e-02 | 1.730 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.862142e-02 | 1.730 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.862142e-02 | 1.730 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.862142e-02 | 1.730 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.872615e-02 | 1.728 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.908070e-02 | 1.719 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.911390e-02 | 1.719 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.976319e-02 | 1.704 | 1 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.992405e-02 | 1.701 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.053815e-02 | 1.687 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.097113e-02 | 1.678 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.142869e-02 | 1.669 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 2.163224e-02 | 1.665 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.212431e-02 | 1.655 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.511140e-02 | 1.600 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.511140e-02 | 1.600 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.667304e-02 | 1.574 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.667304e-02 | 1.574 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.667304e-02 | 1.574 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.667304e-02 | 1.574 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.667304e-02 | 1.574 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.454359e-02 | 1.610 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.511140e-02 | 1.600 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.667304e-02 | 1.574 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 2.667304e-02 | 1.574 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.243951e-02 | 1.649 | 1 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.475054e-02 | 1.606 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.488311e-02 | 1.604 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.677663e-02 | 1.572 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.500965e-02 | 1.602 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.511140e-02 | 1.600 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.356210e-02 | 1.628 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.784618e-02 | 1.555 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 2.829466e-02 | 1.548 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.848663e-02 | 1.545 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 2.848663e-02 | 1.545 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.896120e-02 | 1.538 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 2.970854e-02 | 1.527 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 2.999591e-02 | 1.523 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 3.037536e-02 | 1.517 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 3.310706e-02 | 1.480 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.320697e-02 | 1.479 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 3.320697e-02 | 1.479 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.417763e-02 | 1.466 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.444654e-02 | 1.463 | 1 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.600902e-02 | 1.444 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.649166e-02 | 1.438 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 3.657245e-02 | 1.437 | 1 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.664387e-02 | 1.436 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 3.700779e-02 | 1.432 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.728422e-02 | 1.428 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 3.728422e-02 | 1.428 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 3.728422e-02 | 1.428 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.745607e-02 | 1.426 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.748181e-02 | 1.426 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.815226e-02 | 1.418 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.815226e-02 | 1.418 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.815226e-02 | 1.418 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.865050e-02 | 1.413 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.865654e-02 | 1.413 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.917086e-02 | 1.407 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.057763e-02 | 1.392 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 4.124437e-02 | 1.385 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.411475e-02 | 1.355 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.466054e-02 | 1.350 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.466054e-02 | 1.350 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.569807e-02 | 1.340 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 4.586180e-02 | 1.339 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.602564e-02 | 1.337 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.719441e-02 | 1.326 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.747363e-02 | 1.324 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.768762e-02 | 1.322 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 4.930337e-02 | 1.307 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 4.930337e-02 | 1.307 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.993171e-02 | 1.302 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 5.123283e-02 | 1.290 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 5.123283e-02 | 1.290 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 5.129129e-02 | 1.290 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.129129e-02 | 1.290 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.129129e-02 | 1.290 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.129129e-02 | 1.290 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.129129e-02 | 1.290 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 6.514396e-02 | 1.186 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 6.514396e-02 | 1.186 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 6.514396e-02 | 1.186 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 6.514396e-02 | 1.186 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.905023e-02 | 1.229 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 5.905023e-02 | 1.229 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 5.905023e-02 | 1.229 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 5.905023e-02 | 1.229 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 5.905023e-02 | 1.229 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.875551e-02 | 1.231 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.408453e-02 | 1.193 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 6.408453e-02 | 1.193 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.408453e-02 | 1.193 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.838380e-02 | 1.234 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.612027e-02 | 1.180 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.612027e-02 | 1.180 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.403716e-02 | 1.267 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 5.272423e-02 | 1.278 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 6.612027e-02 | 1.180 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 5.838380e-02 | 1.234 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 6.624585e-02 | 1.179 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.321572e-02 | 1.199 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 5.272423e-02 | 1.278 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 6.703309e-02 | 1.174 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.783777e-02 | 1.169 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 5.272423e-02 | 1.278 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 5.498548e-02 | 1.260 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 6.408453e-02 | 1.193 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 6.408453e-02 | 1.193 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.272423e-02 | 1.278 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.272423e-02 | 1.278 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 5.741636e-02 | 1.241 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 6.408453e-02 | 1.193 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 6.408453e-02 | 1.193 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.291942e-02 | 1.276 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.961739e-02 | 1.157 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 6.408453e-02 | 1.193 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 6.984026e-02 | 1.156 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 7.162515e-02 | 1.145 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 7.198781e-02 | 1.143 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 7.198781e-02 | 1.143 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 7.198781e-02 | 1.143 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 7.198781e-02 | 1.143 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 7.198781e-02 | 1.143 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 7.338053e-02 | 1.134 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 7.338053e-02 | 1.134 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.338053e-02 | 1.134 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 7.338053e-02 | 1.134 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.373960e-02 | 1.132 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.444551e-02 | 1.128 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.544772e-02 | 1.122 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 7.699356e-02 | 1.114 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.699356e-02 | 1.114 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.825553e-02 | 1.106 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 7.920756e-02 | 1.101 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 7.935681e-02 | 1.100 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 8.172508e-02 | 1.088 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 8.624119e-02 | 1.064 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 8.647947e-02 | 1.063 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 8.647947e-02 | 1.063 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 8.647947e-02 | 1.063 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 8.647947e-02 | 1.063 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 8.647947e-02 | 1.063 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 8.647947e-02 | 1.063 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 8.682847e-02 | 1.061 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 8.682847e-02 | 1.061 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.282607e-02 | 1.032 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 9.285764e-02 | 1.032 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 9.414806e-02 | 1.026 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 9.414806e-02 | 1.026 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 9.487026e-02 | 1.023 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 9.527895e-02 | 1.021 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 9.527895e-02 | 1.021 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 9.533571e-02 | 1.021 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 9.707410e-02 | 1.013 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 9.754464e-02 | 1.011 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 9.817789e-02 | 1.008 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 9.817789e-02 | 1.008 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 9.817789e-02 | 1.008 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 9.817789e-02 | 1.008 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 9.817789e-02 | 1.008 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 9.817789e-02 | 1.008 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 9.817789e-02 | 1.008 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 9.817789e-02 | 1.008 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 9.817789e-02 | 1.008 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 9.817789e-02 | 1.008 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 9.873948e-02 | 1.006 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.017490e-01 | 0.992 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.017490e-01 | 0.992 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.017490e-01 | 0.992 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.029336e-01 | 0.987 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.033306e-01 | 0.986 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.033306e-01 | 0.986 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.041703e-01 | 0.982 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.055958e-01 | 0.976 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.055958e-01 | 0.976 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.059859e-01 | 0.975 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.060209e-01 | 0.975 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.065938e-01 | 0.972 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.070192e-01 | 0.971 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.070192e-01 | 0.971 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.070192e-01 | 0.971 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.122053e-01 | 0.950 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.135765e-01 | 0.945 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.135765e-01 | 0.945 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.135765e-01 | 0.945 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.177287e-01 | 0.929 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.184365e-01 | 0.927 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.184365e-01 | 0.927 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 1.184365e-01 | 0.927 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.285093e-01 | 0.891 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 1.285093e-01 | 0.891 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.285093e-01 | 0.891 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 1.285093e-01 | 0.891 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 1.639375e-01 | 0.785 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.639375e-01 | 0.785 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.639375e-01 | 0.785 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.639375e-01 | 0.785 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 1.639375e-01 | 0.785 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 1.639375e-01 | 0.785 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.292416e-01 | 0.889 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.292416e-01 | 0.889 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.529223e-01 | 0.816 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.362180e-01 | 0.866 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.200809e-01 | 0.921 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.549997e-01 | 0.810 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.746816e-01 | 0.758 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.746816e-01 | 0.758 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.365063e-01 | 0.865 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 1.725804e-01 | 0.763 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.214888e-01 | 0.915 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.510400e-01 | 0.821 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.305350e-01 | 0.884 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.773559e-01 | 0.751 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.292416e-01 | 0.889 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.415524e-01 | 0.849 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.529223e-01 | 0.816 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.365063e-01 | 0.865 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 1.285093e-01 | 0.891 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 1.725804e-01 | 0.763 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.256187e-01 | 0.901 | 1 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.493964e-01 | 0.826 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.566749e-01 | 0.805 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.362180e-01 | 0.866 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.321344e-01 | 0.879 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 1.292416e-01 | 0.889 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.746816e-01 | 0.758 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 1.639375e-01 | 0.785 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.599715e-01 | 0.796 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.365063e-01 | 0.865 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.615047e-01 | 0.792 | 1 | 1 |
| Signaling by PTK6 | R-HSA-8848021 | 1.236595e-01 | 0.908 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.236595e-01 | 0.908 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.579819e-01 | 0.801 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.487575e-01 | 0.828 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 1.321899e-01 | 0.879 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.549997e-01 | 0.810 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.506184e-01 | 0.822 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.458416e-01 | 0.836 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.285093e-01 | 0.891 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 1.285093e-01 | 0.891 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 1.292416e-01 | 0.889 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.292416e-01 | 0.889 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.349629e-01 | 0.870 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 1.506184e-01 | 0.822 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.718015e-01 | 0.765 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.321344e-01 | 0.879 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.744311e-01 | 0.758 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 1.748499e-01 | 0.757 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.375553e-01 | 0.862 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.247729e-01 | 0.904 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.292416e-01 | 0.889 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 1.439513e-01 | 0.842 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.407535e-01 | 0.852 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.529223e-01 | 0.816 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.669940e-01 | 0.777 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 1.311737e-01 | 0.882 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 1.627420e-01 | 0.789 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.510400e-01 | 0.821 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 1.639375e-01 | 0.785 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.639375e-01 | 0.785 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 1.292416e-01 | 0.889 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.778350e-01 | 0.750 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.639375e-01 | 0.785 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.219002e-01 | 0.914 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.687590e-01 | 0.773 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.784064e-01 | 0.749 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.840321e-01 | 0.735 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 1.867221e-01 | 0.729 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.867221e-01 | 0.729 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.867221e-01 | 0.729 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.867221e-01 | 0.729 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 1.867221e-01 | 0.729 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.867221e-01 | 0.729 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.867221e-01 | 0.729 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.867221e-01 | 0.729 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.877094e-01 | 0.727 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.885111e-01 | 0.725 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.951599e-01 | 0.710 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.003547e-01 | 0.698 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.008124e-01 | 0.697 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.008124e-01 | 0.697 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 2.008124e-01 | 0.697 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 2.008124e-01 | 0.697 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.016725e-01 | 0.695 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.016725e-01 | 0.695 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.016725e-01 | 0.695 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 2.665774e-01 | 0.574 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 2.665774e-01 | 0.574 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 2.665774e-01 | 0.574 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 2.665774e-01 | 0.574 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 2.665774e-01 | 0.574 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.385960e-01 | 0.470 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.385960e-01 | 0.470 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 3.385960e-01 | 0.470 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 3.385960e-01 | 0.470 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 3.385960e-01 | 0.470 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 3.385960e-01 | 0.470 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 3.385960e-01 | 0.470 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.385960e-01 | 0.470 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 2.037568e-01 | 0.691 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.037568e-01 | 0.691 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 2.037568e-01 | 0.691 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.765107e-01 | 0.558 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.765107e-01 | 0.558 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.765107e-01 | 0.558 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 2.765107e-01 | 0.558 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 4.035466e-01 | 0.394 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 4.035466e-01 | 0.394 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.035466e-01 | 0.394 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.035466e-01 | 0.394 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.035466e-01 | 0.394 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 4.035466e-01 | 0.394 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.304725e-01 | 0.637 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.304725e-01 | 0.637 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.304725e-01 | 0.637 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.304725e-01 | 0.637 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.143946e-01 | 0.503 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 3.143946e-01 | 0.503 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.577774e-01 | 0.589 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.577774e-01 | 0.589 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.518177e-01 | 0.454 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 3.518177e-01 | 0.454 | 1 | 1 |
| Lipophagy | R-HSA-9613354 | 3.518177e-01 | 0.454 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 3.518177e-01 | 0.454 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 3.518177e-01 | 0.454 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.134017e-01 | 0.504 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 3.134017e-01 | 0.504 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 3.134017e-01 | 0.504 | 1 | 1 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.829230e-01 | 0.548 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.829230e-01 | 0.548 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.829230e-01 | 0.548 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 3.885054e-01 | 0.411 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.885054e-01 | 0.411 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 3.885054e-01 | 0.411 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.885054e-01 | 0.411 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 3.885054e-01 | 0.411 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 3.885054e-01 | 0.411 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 3.413807e-01 | 0.467 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.769868e-01 | 0.558 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 2.527155e-01 | 0.597 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 2.527155e-01 | 0.597 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.966812e-01 | 0.528 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.692694e-01 | 0.433 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.692694e-01 | 0.433 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 3.165944e-01 | 0.499 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.165944e-01 | 0.499 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.109917e-01 | 0.676 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.969358e-01 | 0.401 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.969358e-01 | 0.401 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 3.969358e-01 | 0.401 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.969358e-01 | 0.401 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 3.751906e-01 | 0.426 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.751906e-01 | 0.426 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.407972e-01 | 0.468 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.264771e-01 | 0.486 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.982758e-01 | 0.400 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.215234e-01 | 0.655 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.405325e-01 | 0.619 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 3.951801e-01 | 0.403 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.407647e-01 | 0.618 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.874186e-01 | 0.412 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.056343e-01 | 0.687 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.380821e-01 | 0.623 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.854797e-01 | 0.544 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.829230e-01 | 0.548 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.571108e-01 | 0.590 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 2.527155e-01 | 0.597 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 3.228110e-01 | 0.491 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.885054e-01 | 0.411 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.765107e-01 | 0.558 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 2.765107e-01 | 0.558 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 3.518177e-01 | 0.454 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.193994e-01 | 0.659 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 3.885054e-01 | 0.411 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 2.358760e-01 | 0.627 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 3.413807e-01 | 0.467 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.568332e-01 | 0.448 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.568332e-01 | 0.448 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.407647e-01 | 0.618 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 3.751906e-01 | 0.426 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.037568e-01 | 0.691 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.304725e-01 | 0.637 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 3.518177e-01 | 0.454 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 3.134017e-01 | 0.504 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 3.885054e-01 | 0.411 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 3.885054e-01 | 0.411 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.692694e-01 | 0.433 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.873052e-01 | 0.542 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.520300e-01 | 0.453 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.647489e-01 | 0.577 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 3.165944e-01 | 0.499 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 3.613064e-01 | 0.442 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 3.613064e-01 | 0.442 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 3.613064e-01 | 0.442 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.515193e-01 | 0.454 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.603144e-01 | 0.585 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.042333e-01 | 0.690 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.760164e-01 | 0.425 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 3.681692e-01 | 0.434 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 2.037568e-01 | 0.691 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.163288e-01 | 0.665 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.163288e-01 | 0.665 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 2.854797e-01 | 0.544 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.518177e-01 | 0.454 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 3.885054e-01 | 0.411 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.885054e-01 | 0.411 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 3.885054e-01 | 0.411 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 3.413807e-01 | 0.467 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 3.413807e-01 | 0.467 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 3.692694e-01 | 0.433 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.692694e-01 | 0.433 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.969358e-01 | 0.401 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.982758e-01 | 0.400 | 1 | 1 |
| Tight junction interactions | R-HSA-420029 | 3.982758e-01 | 0.400 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 2.075270e-01 | 0.683 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.049658e-01 | 0.516 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.163288e-01 | 0.665 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 2.564325e-01 | 0.591 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.033296e-01 | 0.692 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.836545e-01 | 0.416 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.564325e-01 | 0.591 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.836545e-01 | 0.416 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 3.518177e-01 | 0.454 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 3.134017e-01 | 0.504 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.217393e-01 | 0.654 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.366649e-01 | 0.473 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.056343e-01 | 0.687 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 2.698735e-01 | 0.569 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 2.854797e-01 | 0.544 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 3.692694e-01 | 0.433 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 3.770419e-01 | 0.424 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.770226e-01 | 0.424 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.972366e-01 | 0.401 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 2.966812e-01 | 0.528 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.877734e-01 | 0.541 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 3.725358e-01 | 0.429 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.380821e-01 | 0.623 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.665774e-01 | 0.574 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 2.665774e-01 | 0.574 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective factor XII causes hereditary angioedema | R-HSA-9657688 | 3.385960e-01 | 0.470 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.385089e-01 | 0.622 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 2.765107e-01 | 0.558 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 2.765107e-01 | 0.558 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.035466e-01 | 0.394 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 4.035466e-01 | 0.394 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 2.304725e-01 | 0.637 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 2.577774e-01 | 0.589 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.163288e-01 | 0.665 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.829230e-01 | 0.548 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.520300e-01 | 0.453 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 3.751906e-01 | 0.426 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 3.015865e-01 | 0.521 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 3.588816e-01 | 0.445 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 3.588816e-01 | 0.445 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.295196e-01 | 0.482 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.303234e-01 | 0.481 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 2.355332e-01 | 0.628 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.193994e-01 | 0.659 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.437819e-01 | 0.464 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 3.996180e-01 | 0.398 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.361185e-01 | 0.627 | 1 | 0 |
| Pexophagy | R-HSA-9664873 | 3.885054e-01 | 0.411 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.317760e-01 | 0.635 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.163288e-01 | 0.665 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.304725e-01 | 0.637 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.877734e-01 | 0.541 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 3.296526e-01 | 0.482 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.380821e-01 | 0.623 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.518177e-01 | 0.454 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 3.885054e-01 | 0.411 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 2.092791e-01 | 0.679 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 2.821992e-01 | 0.549 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.623858e-01 | 0.581 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 3.290785e-01 | 0.483 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.765107e-01 | 0.558 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.765107e-01 | 0.558 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.518177e-01 | 0.454 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.603144e-01 | 0.585 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 2.575744e-01 | 0.589 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.035911e-01 | 0.518 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 3.049658e-01 | 0.516 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.804023e-01 | 0.420 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.803255e-01 | 0.552 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.665774e-01 | 0.574 | 0 | 0 |
| Defective SERPING1 causes hereditary angioedema | R-HSA-9657689 | 2.665774e-01 | 0.574 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.035466e-01 | 0.394 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.518177e-01 | 0.454 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 2.193994e-01 | 0.659 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 3.413807e-01 | 0.467 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.285776e-01 | 0.483 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.588816e-01 | 0.445 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.561544e-01 | 0.591 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.035466e-01 | 0.394 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 3.869559e-01 | 0.412 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.777937e-01 | 0.423 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.165944e-01 | 0.499 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 2.665774e-01 | 0.574 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.385960e-01 | 0.470 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 3.385960e-01 | 0.470 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 2.385089e-01 | 0.622 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.304725e-01 | 0.637 | 0 | 0 |
| RSK activation | R-HSA-444257 | 3.143946e-01 | 0.503 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 2.163288e-01 | 0.665 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.885054e-01 | 0.411 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 3.885054e-01 | 0.411 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 3.413807e-01 | 0.467 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.217393e-01 | 0.654 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 3.407972e-01 | 0.468 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 3.413807e-01 | 0.467 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 2.854797e-01 | 0.544 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.198525e-01 | 0.658 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.458787e-01 | 0.461 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.518177e-01 | 0.454 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.575744e-01 | 0.589 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 2.304725e-01 | 0.637 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.143946e-01 | 0.503 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.854797e-01 | 0.544 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.518177e-01 | 0.454 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.518177e-01 | 0.454 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.163288e-01 | 0.665 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 3.146072e-01 | 0.502 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 2.037568e-01 | 0.691 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 3.885054e-01 | 0.411 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 3.692694e-01 | 0.433 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.770419e-01 | 0.424 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 3.143946e-01 | 0.503 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 3.625318e-01 | 0.441 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 3.518177e-01 | 0.454 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 3.885054e-01 | 0.411 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 2.024727e-01 | 0.694 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.052824e-01 | 0.392 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.052824e-01 | 0.392 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.052824e-01 | 0.392 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.052824e-01 | 0.392 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.052824e-01 | 0.392 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.158631e-01 | 0.381 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.158631e-01 | 0.381 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 4.173653e-01 | 0.379 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 4.173653e-01 | 0.379 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 4.173653e-01 | 0.379 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 4.212116e-01 | 0.375 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.212116e-01 | 0.375 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.212116e-01 | 0.375 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 4.212116e-01 | 0.375 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.242415e-01 | 0.372 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.242415e-01 | 0.372 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.242415e-01 | 0.372 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.242415e-01 | 0.372 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.242415e-01 | 0.372 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 4.242627e-01 | 0.372 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.242627e-01 | 0.372 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 4.254195e-01 | 0.371 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.258604e-01 | 0.371 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.343832e-01 | 0.362 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.360996e-01 | 0.360 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 4.373793e-01 | 0.359 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.424042e-01 | 0.354 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.439301e-01 | 0.353 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.439301e-01 | 0.353 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.439301e-01 | 0.353 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 4.439301e-01 | 0.353 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 4.447298e-01 | 0.352 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 4.462349e-01 | 0.350 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 4.493724e-01 | 0.347 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.511475e-01 | 0.346 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 4.511475e-01 | 0.346 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 4.511475e-01 | 0.346 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.511475e-01 | 0.346 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.511475e-01 | 0.346 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.511475e-01 | 0.346 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 4.511475e-01 | 0.346 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.514436e-01 | 0.345 | 0 | 0 |
| Disease | R-HSA-1643685 | 4.568304e-01 | 0.340 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 4.572329e-01 | 0.340 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.572329e-01 | 0.340 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 4.572329e-01 | 0.340 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.572329e-01 | 0.340 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.588591e-01 | 0.338 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.588591e-01 | 0.338 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.588591e-01 | 0.338 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.591014e-01 | 0.338 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 4.599113e-01 | 0.337 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 4.599113e-01 | 0.337 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.621224e-01 | 0.335 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 4.621224e-01 | 0.335 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.621224e-01 | 0.335 | 0 | 0 |
| Extrinsic Pathway of Fibrin Clot Formation | R-HSA-140834 | 4.621224e-01 | 0.335 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.621224e-01 | 0.335 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.621224e-01 | 0.335 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 4.621224e-01 | 0.335 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 4.663692e-01 | 0.331 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 4.665946e-01 | 0.331 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.672259e-01 | 0.330 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.726830e-01 | 0.325 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.734080e-01 | 0.325 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.734080e-01 | 0.325 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 4.775017e-01 | 0.321 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 4.775017e-01 | 0.321 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 4.775017e-01 | 0.321 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 4.775017e-01 | 0.321 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.775017e-01 | 0.321 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 4.775017e-01 | 0.321 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 4.775017e-01 | 0.321 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.775017e-01 | 0.321 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 4.775017e-01 | 0.321 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 4.848462e-01 | 0.314 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.849202e-01 | 0.314 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.849202e-01 | 0.314 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.849202e-01 | 0.314 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 4.878785e-01 | 0.312 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 4.884730e-01 | 0.311 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 4.884730e-01 | 0.311 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 4.906803e-01 | 0.309 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 4.922334e-01 | 0.308 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.922334e-01 | 0.308 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 4.922334e-01 | 0.308 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 4.922334e-01 | 0.308 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.922334e-01 | 0.308 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.922334e-01 | 0.308 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.922334e-01 | 0.308 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 4.922334e-01 | 0.308 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 4.922334e-01 | 0.308 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 4.922334e-01 | 0.308 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.922334e-01 | 0.308 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.922334e-01 | 0.308 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.962927e-01 | 0.304 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 4.962927e-01 | 0.304 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 4.962927e-01 | 0.304 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.972379e-01 | 0.303 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 5.008876e-01 | 0.300 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 5.024261e-01 | 0.299 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 5.024261e-01 | 0.299 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 5.032493e-01 | 0.298 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 5.032493e-01 | 0.298 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.032493e-01 | 0.298 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 5.032493e-01 | 0.298 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 5.032493e-01 | 0.298 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.060175e-01 | 0.296 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.118998e-01 | 0.291 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.147084e-01 | 0.288 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 5.149488e-01 | 0.288 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 5.149488e-01 | 0.288 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.149488e-01 | 0.288 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.149488e-01 | 0.288 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.149488e-01 | 0.288 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.149488e-01 | 0.288 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.149488e-01 | 0.288 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.149488e-01 | 0.288 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.149488e-01 | 0.288 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.149488e-01 | 0.288 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.149488e-01 | 0.288 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.149488e-01 | 0.288 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 5.149488e-01 | 0.288 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 5.149488e-01 | 0.288 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.149488e-01 | 0.288 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 5.154239e-01 | 0.288 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.197162e-01 | 0.284 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 5.197162e-01 | 0.284 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.242748e-01 | 0.280 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.242748e-01 | 0.280 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 5.242748e-01 | 0.280 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.242748e-01 | 0.280 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 5.253818e-01 | 0.280 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.253818e-01 | 0.280 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 5.283270e-01 | 0.277 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.283270e-01 | 0.277 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 5.283270e-01 | 0.277 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.296572e-01 | 0.276 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.314808e-01 | 0.275 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.342447e-01 | 0.272 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 5.376113e-01 | 0.270 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.391086e-01 | 0.268 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.391086e-01 | 0.268 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.433996e-01 | 0.265 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 5.456744e-01 | 0.263 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 5.526824e-01 | 0.258 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 5.526824e-01 | 0.258 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 5.526824e-01 | 0.258 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.526824e-01 | 0.258 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.527259e-01 | 0.257 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.531562e-01 | 0.257 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.549231e-01 | 0.256 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.549231e-01 | 0.256 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.549231e-01 | 0.256 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 5.549231e-01 | 0.256 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.549231e-01 | 0.256 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.557548e-01 | 0.255 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.557548e-01 | 0.255 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.625897e-01 | 0.250 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.625897e-01 | 0.250 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 5.625897e-01 | 0.250 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 5.625897e-01 | 0.250 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 5.625897e-01 | 0.250 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.625897e-01 | 0.250 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 5.625897e-01 | 0.250 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 5.625897e-01 | 0.250 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.625897e-01 | 0.250 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 5.625897e-01 | 0.250 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.625897e-01 | 0.250 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 5.625897e-01 | 0.250 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 5.625897e-01 | 0.250 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 5.625897e-01 | 0.250 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 5.625897e-01 | 0.250 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 5.625897e-01 | 0.250 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 5.625897e-01 | 0.250 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 5.672130e-01 | 0.246 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.698433e-01 | 0.244 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 5.708414e-01 | 0.243 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.716624e-01 | 0.243 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.716624e-01 | 0.243 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.716624e-01 | 0.243 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 5.720730e-01 | 0.243 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.726219e-01 | 0.242 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.841429e-01 | 0.233 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 5.841429e-01 | 0.233 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 5.841429e-01 | 0.233 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 5.841429e-01 | 0.233 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 5.841429e-01 | 0.233 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.841429e-01 | 0.233 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 5.841429e-01 | 0.233 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 5.841429e-01 | 0.233 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 5.841429e-01 | 0.233 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.848468e-01 | 0.233 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 5.848468e-01 | 0.233 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.862476e-01 | 0.232 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 5.862476e-01 | 0.232 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 5.924124e-01 | 0.227 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.954708e-01 | 0.225 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 5.990683e-01 | 0.223 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 6.021232e-01 | 0.220 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.021232e-01 | 0.220 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.055540e-01 | 0.218 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.055540e-01 | 0.218 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.055540e-01 | 0.218 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 6.055540e-01 | 0.218 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 6.055540e-01 | 0.218 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.055540e-01 | 0.218 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.055540e-01 | 0.218 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 6.055540e-01 | 0.218 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.055540e-01 | 0.218 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 6.058857e-01 | 0.218 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 6.064319e-01 | 0.217 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 6.095449e-01 | 0.215 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 6.116501e-01 | 0.213 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 6.116501e-01 | 0.213 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 6.119192e-01 | 0.213 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 6.119192e-01 | 0.213 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.119192e-01 | 0.213 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 6.119192e-01 | 0.213 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.119192e-01 | 0.213 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 6.119192e-01 | 0.213 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.119192e-01 | 0.213 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.119192e-01 | 0.213 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.119192e-01 | 0.213 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.119192e-01 | 0.213 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 6.140543e-01 | 0.212 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 6.140543e-01 | 0.212 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 6.154381e-01 | 0.211 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 6.165865e-01 | 0.210 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.165865e-01 | 0.210 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 6.210425e-01 | 0.207 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 6.210425e-01 | 0.207 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 6.210425e-01 | 0.207 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 6.246295e-01 | 0.204 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.247929e-01 | 0.204 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 6.282336e-01 | 0.202 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 6.320351e-01 | 0.199 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 6.374369e-01 | 0.196 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 6.382536e-01 | 0.195 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.382536e-01 | 0.195 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 6.382536e-01 | 0.195 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.382536e-01 | 0.195 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 6.382536e-01 | 0.195 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 6.382536e-01 | 0.195 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 6.392285e-01 | 0.194 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.421802e-01 | 0.192 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.421802e-01 | 0.192 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 6.421802e-01 | 0.192 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.433291e-01 | 0.192 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 6.436828e-01 | 0.191 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.443004e-01 | 0.191 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.443004e-01 | 0.191 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 6.443004e-01 | 0.191 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.443004e-01 | 0.191 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.443004e-01 | 0.191 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.443004e-01 | 0.191 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.443004e-01 | 0.191 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 6.443004e-01 | 0.191 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.443004e-01 | 0.191 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.468069e-01 | 0.189 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.476409e-01 | 0.189 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.476409e-01 | 0.189 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 6.483957e-01 | 0.188 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 6.483957e-01 | 0.188 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.483957e-01 | 0.188 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 6.552272e-01 | 0.184 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.556689e-01 | 0.183 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 6.587736e-01 | 0.181 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 6.624721e-01 | 0.179 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 6.624721e-01 | 0.179 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 6.624721e-01 | 0.179 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 6.624721e-01 | 0.179 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 6.624721e-01 | 0.179 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.631614e-01 | 0.178 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 6.631614e-01 | 0.178 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.631614e-01 | 0.178 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.631614e-01 | 0.178 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.658783e-01 | 0.177 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 6.689549e-01 | 0.175 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.755783e-01 | 0.170 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 6.762293e-01 | 0.170 | 0 | 0 |
| ALKBH3 mediated reversal of alkylation damage | R-HSA-112126 | 6.792429e-01 | 0.168 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 6.792429e-01 | 0.168 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 6.792429e-01 | 0.168 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.792429e-01 | 0.168 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 6.792429e-01 | 0.168 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.792429e-01 | 0.168 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 6.792429e-01 | 0.168 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 6.792429e-01 | 0.168 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.792429e-01 | 0.168 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 6.792429e-01 | 0.168 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 6.792429e-01 | 0.168 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 6.792429e-01 | 0.168 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.792429e-01 | 0.168 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 6.792429e-01 | 0.168 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.792429e-01 | 0.168 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 6.792429e-01 | 0.168 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 6.792429e-01 | 0.168 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 6.792429e-01 | 0.168 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.818973e-01 | 0.166 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.819151e-01 | 0.166 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.819151e-01 | 0.166 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 6.819151e-01 | 0.166 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 6.819151e-01 | 0.166 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 6.858321e-01 | 0.164 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 6.858321e-01 | 0.164 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.866686e-01 | 0.163 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 6.866686e-01 | 0.163 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.866686e-01 | 0.163 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.866686e-01 | 0.163 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 6.866686e-01 | 0.163 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.866686e-01 | 0.163 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.866686e-01 | 0.163 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 6.868818e-01 | 0.163 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.941586e-01 | 0.159 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.945143e-01 | 0.158 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 6.990266e-01 | 0.156 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.004263e-01 | 0.155 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 7.005112e-01 | 0.155 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 7.005112e-01 | 0.155 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.005112e-01 | 0.155 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 7.005112e-01 | 0.155 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.005112e-01 | 0.155 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 7.005112e-01 | 0.155 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.005112e-01 | 0.155 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.041635e-01 | 0.152 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.088100e-01 | 0.149 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 7.088100e-01 | 0.149 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 7.088100e-01 | 0.149 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.107546e-01 | 0.148 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.107546e-01 | 0.148 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 7.107546e-01 | 0.148 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.107546e-01 | 0.148 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.107546e-01 | 0.148 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.145439e-01 | 0.146 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 7.146876e-01 | 0.146 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.146876e-01 | 0.146 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 7.161604e-01 | 0.145 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.182675e-01 | 0.144 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.182675e-01 | 0.144 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.182675e-01 | 0.144 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 7.182675e-01 | 0.144 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 7.182675e-01 | 0.144 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.182675e-01 | 0.144 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.187563e-01 | 0.143 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 7.266543e-01 | 0.139 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.280459e-01 | 0.138 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.281837e-01 | 0.138 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 7.296271e-01 | 0.137 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.296271e-01 | 0.137 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.297413e-01 | 0.137 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.303760e-01 | 0.136 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 7.351948e-01 | 0.134 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 7.351948e-01 | 0.134 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.351948e-01 | 0.134 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 7.391722e-01 | 0.131 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.391722e-01 | 0.131 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.391722e-01 | 0.131 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.391722e-01 | 0.131 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.391722e-01 | 0.131 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 7.391722e-01 | 0.131 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 7.391722e-01 | 0.131 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 7.408186e-01 | 0.130 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 7.416598e-01 | 0.130 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.421040e-01 | 0.130 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 7.441919e-01 | 0.128 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 7.441919e-01 | 0.128 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 7.491662e-01 | 0.125 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.491662e-01 | 0.125 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.491662e-01 | 0.125 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.491662e-01 | 0.125 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 7.513075e-01 | 0.124 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.526073e-01 | 0.123 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.571798e-01 | 0.121 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.647993e-01 | 0.116 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 7.647993e-01 | 0.116 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 7.647993e-01 | 0.116 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 7.647993e-01 | 0.116 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.647993e-01 | 0.116 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.647993e-01 | 0.116 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.647993e-01 | 0.116 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 7.647993e-01 | 0.116 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 7.647993e-01 | 0.116 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.647993e-01 | 0.116 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 7.647993e-01 | 0.116 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.647993e-01 | 0.116 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.663588e-01 | 0.116 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 7.666229e-01 | 0.115 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.666229e-01 | 0.115 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 7.666229e-01 | 0.115 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.674776e-01 | 0.115 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 7.674776e-01 | 0.115 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 7.674776e-01 | 0.115 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.674776e-01 | 0.115 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.674776e-01 | 0.115 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.683349e-01 | 0.114 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.739118e-01 | 0.111 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 7.766516e-01 | 0.110 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 7.811607e-01 | 0.107 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 7.811607e-01 | 0.107 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.811607e-01 | 0.107 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.814358e-01 | 0.107 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 7.828286e-01 | 0.106 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.839986e-01 | 0.106 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 7.839986e-01 | 0.106 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 7.846138e-01 | 0.105 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.846138e-01 | 0.105 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.846138e-01 | 0.105 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.846138e-01 | 0.105 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.846138e-01 | 0.105 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 7.846138e-01 | 0.105 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.879099e-01 | 0.104 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 7.879099e-01 | 0.104 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 7.879099e-01 | 0.104 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 7.879099e-01 | 0.104 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.879099e-01 | 0.104 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 7.879099e-01 | 0.104 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 7.879099e-01 | 0.104 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 7.879099e-01 | 0.104 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 7.879099e-01 | 0.104 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.892931e-01 | 0.103 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.918237e-01 | 0.101 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 7.949427e-01 | 0.100 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 7.949427e-01 | 0.100 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 7.961187e-01 | 0.099 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 7.961187e-01 | 0.099 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 8.001312e-01 | 0.097 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 8.001312e-01 | 0.097 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 8.006289e-01 | 0.097 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 8.006289e-01 | 0.097 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.006289e-01 | 0.097 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 8.006289e-01 | 0.097 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 8.076846e-01 | 0.093 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.076846e-01 | 0.093 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.079920e-01 | 0.093 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.079920e-01 | 0.093 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 8.087509e-01 | 0.092 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.087509e-01 | 0.092 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 8.087509e-01 | 0.092 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.087509e-01 | 0.092 | 0 | 0 |
| Acetylation | R-HSA-156582 | 8.087509e-01 | 0.092 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 8.087509e-01 | 0.092 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.087509e-01 | 0.092 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 8.087509e-01 | 0.092 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.087509e-01 | 0.092 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.087509e-01 | 0.092 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.087509e-01 | 0.092 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 8.087509e-01 | 0.092 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 8.155777e-01 | 0.089 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.155777e-01 | 0.089 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 8.203333e-01 | 0.086 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.254079e-01 | 0.083 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.275450e-01 | 0.082 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.275450e-01 | 0.082 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.275450e-01 | 0.082 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.275450e-01 | 0.082 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.275450e-01 | 0.082 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.275450e-01 | 0.082 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 8.275450e-01 | 0.082 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.275450e-01 | 0.082 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.275450e-01 | 0.082 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.275450e-01 | 0.082 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 8.275450e-01 | 0.082 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.275450e-01 | 0.082 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.295150e-01 | 0.081 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.295150e-01 | 0.081 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 8.295150e-01 | 0.081 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 8.319919e-01 | 0.080 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.319919e-01 | 0.080 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.319919e-01 | 0.080 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 8.357523e-01 | 0.078 | 0 | 0 |
| Immune System | R-HSA-168256 | 8.360428e-01 | 0.078 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.424954e-01 | 0.074 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.424954e-01 | 0.074 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.429939e-01 | 0.074 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.444933e-01 | 0.073 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.444933e-01 | 0.073 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 8.444933e-01 | 0.073 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.444933e-01 | 0.073 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.444933e-01 | 0.073 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.444933e-01 | 0.073 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.444933e-01 | 0.073 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 8.444933e-01 | 0.073 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.444933e-01 | 0.073 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.444933e-01 | 0.073 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.444933e-01 | 0.073 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.444933e-01 | 0.073 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.444933e-01 | 0.073 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.478384e-01 | 0.072 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 8.486909e-01 | 0.071 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 8.490682e-01 | 0.071 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 8.533657e-01 | 0.069 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 8.545721e-01 | 0.068 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.545721e-01 | 0.068 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 8.545721e-01 | 0.068 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.545721e-01 | 0.068 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.567617e-01 | 0.067 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 8.577059e-01 | 0.067 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.594708e-01 | 0.066 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.597768e-01 | 0.066 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.597768e-01 | 0.066 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 8.597768e-01 | 0.066 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 8.597768e-01 | 0.066 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.597768e-01 | 0.066 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.597768e-01 | 0.066 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.597768e-01 | 0.066 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.597768e-01 | 0.066 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.597768e-01 | 0.066 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.597768e-01 | 0.066 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 8.597768e-01 | 0.066 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.597768e-01 | 0.066 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 8.612944e-01 | 0.065 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 8.631340e-01 | 0.064 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.631340e-01 | 0.064 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 8.631340e-01 | 0.064 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 8.631340e-01 | 0.064 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.631340e-01 | 0.064 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.631340e-01 | 0.064 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 8.631340e-01 | 0.064 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 8.631340e-01 | 0.064 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.631340e-01 | 0.064 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 8.644185e-01 | 0.063 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.657973e-01 | 0.063 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.657973e-01 | 0.063 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 8.657973e-01 | 0.063 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 8.662588e-01 | 0.062 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 8.662588e-01 | 0.062 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 8.662588e-01 | 0.062 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.680515e-01 | 0.061 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 8.720531e-01 | 0.059 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.729652e-01 | 0.059 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.735591e-01 | 0.059 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.735591e-01 | 0.059 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 8.735591e-01 | 0.059 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 8.735591e-01 | 0.059 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.738704e-01 | 0.059 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 8.743665e-01 | 0.058 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.762219e-01 | 0.057 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 8.762219e-01 | 0.057 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 8.762219e-01 | 0.057 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 8.779232e-01 | 0.057 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.809657e-01 | 0.055 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.809657e-01 | 0.055 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.809657e-01 | 0.055 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.809657e-01 | 0.055 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.858946e-01 | 0.053 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.858946e-01 | 0.053 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 8.859874e-01 | 0.053 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.859874e-01 | 0.053 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 8.859874e-01 | 0.053 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 8.859874e-01 | 0.053 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.859874e-01 | 0.053 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 8.859874e-01 | 0.053 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.859874e-01 | 0.053 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.859874e-01 | 0.053 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 8.859874e-01 | 0.053 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 8.859874e-01 | 0.053 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.859874e-01 | 0.053 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 8.893132e-01 | 0.051 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.893132e-01 | 0.051 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.909663e-01 | 0.050 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 8.915751e-01 | 0.050 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 8.922242e-01 | 0.050 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 8.948625e-01 | 0.048 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 8.948625e-01 | 0.048 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.948625e-01 | 0.048 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.961859e-01 | 0.048 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 8.962169e-01 | 0.048 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.966984e-01 | 0.047 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 8.971948e-01 | 0.047 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 8.971948e-01 | 0.047 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 8.971948e-01 | 0.047 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 8.971948e-01 | 0.047 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 8.971948e-01 | 0.047 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 8.971948e-01 | 0.047 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 8.971948e-01 | 0.047 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 8.971948e-01 | 0.047 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.011328e-01 | 0.045 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.031706e-01 | 0.044 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 9.031706e-01 | 0.044 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.062146e-01 | 0.043 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.073011e-01 | 0.042 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.073011e-01 | 0.042 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.073011e-01 | 0.042 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.073011e-01 | 0.042 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.073011e-01 | 0.042 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.088128e-01 | 0.042 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.096725e-01 | 0.041 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 9.098896e-01 | 0.041 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.105344e-01 | 0.041 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.105344e-01 | 0.041 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.105344e-01 | 0.041 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.105344e-01 | 0.041 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.107088e-01 | 0.041 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.108621e-01 | 0.041 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.108621e-01 | 0.041 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.143836e-01 | 0.039 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.145994e-01 | 0.039 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.145994e-01 | 0.039 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.145994e-01 | 0.039 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.164145e-01 | 0.038 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.164145e-01 | 0.038 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.164145e-01 | 0.038 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.164145e-01 | 0.038 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.168017e-01 | 0.038 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.168017e-01 | 0.038 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 9.179777e-01 | 0.037 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 9.179777e-01 | 0.037 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.179777e-01 | 0.037 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.200559e-01 | 0.036 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.218669e-01 | 0.035 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.226661e-01 | 0.035 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.229508e-01 | 0.035 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 9.245564e-01 | 0.034 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.245564e-01 | 0.034 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.245564e-01 | 0.034 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.245564e-01 | 0.034 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.246323e-01 | 0.034 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 9.246323e-01 | 0.034 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.246323e-01 | 0.034 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.246323e-01 | 0.034 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.246323e-01 | 0.034 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.246323e-01 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.246323e-01 | 0.034 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.246323e-01 | 0.034 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.246323e-01 | 0.034 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.273184e-01 | 0.033 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.300398e-01 | 0.031 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.300398e-01 | 0.031 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.306348e-01 | 0.031 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.306348e-01 | 0.031 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.320427e-01 | 0.031 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.320427e-01 | 0.031 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.320427e-01 | 0.031 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.320427e-01 | 0.031 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.320427e-01 | 0.031 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.320427e-01 | 0.031 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.320427e-01 | 0.031 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 9.320427e-01 | 0.031 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.320427e-01 | 0.031 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.320427e-01 | 0.031 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.320427e-01 | 0.031 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.320427e-01 | 0.031 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 9.332739e-01 | 0.030 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 9.332739e-01 | 0.030 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.377562e-01 | 0.028 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.380592e-01 | 0.028 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.380592e-01 | 0.028 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.381160e-01 | 0.028 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.387248e-01 | 0.027 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.387248e-01 | 0.027 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.387248e-01 | 0.027 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.387248e-01 | 0.027 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.414282e-01 | 0.026 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.416768e-01 | 0.026 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.447503e-01 | 0.025 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.447503e-01 | 0.025 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.447503e-01 | 0.025 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.447503e-01 | 0.025 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.462066e-01 | 0.024 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.466910e-01 | 0.024 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.466972e-01 | 0.024 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.493483e-01 | 0.023 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.501836e-01 | 0.022 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.501836e-01 | 0.022 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.501836e-01 | 0.022 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.501836e-01 | 0.022 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.501836e-01 | 0.022 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 9.505743e-01 | 0.022 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.505743e-01 | 0.022 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.506120e-01 | 0.022 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 9.506120e-01 | 0.022 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.507118e-01 | 0.022 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 9.517575e-01 | 0.021 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.541924e-01 | 0.020 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.549547e-01 | 0.020 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.550828e-01 | 0.020 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.550828e-01 | 0.020 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.550828e-01 | 0.020 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.550828e-01 | 0.020 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.550828e-01 | 0.020 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.550828e-01 | 0.020 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.550828e-01 | 0.020 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.576252e-01 | 0.019 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.584106e-01 | 0.018 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.584106e-01 | 0.018 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.584106e-01 | 0.018 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.595005e-01 | 0.018 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.595005e-01 | 0.018 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.595005e-01 | 0.018 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.595005e-01 | 0.018 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.595005e-01 | 0.018 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.595005e-01 | 0.018 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.595005e-01 | 0.018 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 9.599091e-01 | 0.018 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.606973e-01 | 0.017 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 9.618529e-01 | 0.017 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.618529e-01 | 0.017 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.618529e-01 | 0.017 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 9.623938e-01 | 0.017 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 9.623938e-01 | 0.017 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.623938e-01 | 0.017 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 9.634839e-01 | 0.016 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.634839e-01 | 0.016 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.634839e-01 | 0.016 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.641712e-01 | 0.016 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.649667e-01 | 0.015 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.650208e-01 | 0.015 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.650208e-01 | 0.015 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.650208e-01 | 0.015 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.663265e-01 | 0.015 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.670758e-01 | 0.015 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.670758e-01 | 0.015 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.670758e-01 | 0.015 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.674468e-01 | 0.014 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.679347e-01 | 0.014 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.680220e-01 | 0.014 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.683896e-01 | 0.014 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.689605e-01 | 0.014 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.703145e-01 | 0.013 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.706141e-01 | 0.013 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.711885e-01 | 0.013 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.730769e-01 | 0.012 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.730769e-01 | 0.012 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.730769e-01 | 0.012 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.730769e-01 | 0.012 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.730956e-01 | 0.012 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.732348e-01 | 0.012 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.732348e-01 | 0.012 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.732348e-01 | 0.012 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.732348e-01 | 0.012 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.733626e-01 | 0.012 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.750357e-01 | 0.011 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.755454e-01 | 0.011 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.763140e-01 | 0.010 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.774180e-01 | 0.010 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.776593e-01 | 0.010 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.782423e-01 | 0.010 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.803831e-01 | 0.009 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.805974e-01 | 0.009 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.810615e-01 | 0.008 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.810777e-01 | 0.008 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.810777e-01 | 0.008 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.810914e-01 | 0.008 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.812324e-01 | 0.008 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.823573e-01 | 0.008 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.834961e-01 | 0.007 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.840538e-01 | 0.007 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.840538e-01 | 0.007 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.840538e-01 | 0.007 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.841591e-01 | 0.007 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.841591e-01 | 0.007 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.856230e-01 | 0.006 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.856230e-01 | 0.006 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.870273e-01 | 0.006 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.870380e-01 | 0.006 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.870380e-01 | 0.006 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.870380e-01 | 0.006 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.880403e-01 | 0.005 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.881193e-01 | 0.005 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.883137e-01 | 0.005 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 9.883137e-01 | 0.005 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.883137e-01 | 0.005 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.885884e-01 | 0.005 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.885884e-01 | 0.005 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.889266e-01 | 0.005 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.894640e-01 | 0.005 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.894640e-01 | 0.005 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.894640e-01 | 0.005 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.902307e-01 | 0.004 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.903045e-01 | 0.004 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.905011e-01 | 0.004 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.905011e-01 | 0.004 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.906533e-01 | 0.004 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.907528e-01 | 0.004 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.914361e-01 | 0.004 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.914361e-01 | 0.004 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.914361e-01 | 0.004 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.915440e-01 | 0.004 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.922792e-01 | 0.003 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.922792e-01 | 0.003 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.922836e-01 | 0.003 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.922836e-01 | 0.003 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.929530e-01 | 0.003 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.930393e-01 | 0.003 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.930393e-01 | 0.003 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.931204e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.931856e-01 | 0.003 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.932764e-01 | 0.003 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.932764e-01 | 0.003 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.935655e-01 | 0.003 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.937246e-01 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.937246e-01 | 0.003 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.943425e-01 | 0.002 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.943425e-01 | 0.002 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.946380e-01 | 0.002 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.948996e-01 | 0.002 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.954019e-01 | 0.002 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.954019e-01 | 0.002 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.956300e-01 | 0.002 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.958547e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.962836e-01 | 0.002 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.962836e-01 | 0.002 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.965578e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.966104e-01 | 0.001 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.966310e-01 | 0.001 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.969854e-01 | 0.001 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.971813e-01 | 0.001 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.973620e-01 | 0.001 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.974302e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.975317e-01 | 0.001 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.975358e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.977551e-01 | 0.001 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.977551e-01 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.980541e-01 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.981917e-01 | 0.001 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.982268e-01 | 0.001 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.983699e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.985398e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.985913e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.986593e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.986593e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.986753e-01 | 0.001 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.987190e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.988740e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.989874e-01 | 0.000 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.991253e-01 | 0.000 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.991606e-01 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.992055e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.992115e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.992172e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.993784e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.994225e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.994240e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.995770e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.996902e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997208e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.997208e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.997483e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.997732e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.997850e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.998202e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.998615e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.998651e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.998692e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.998784e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.998846e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.998903e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.998928e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999304e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999563e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999570e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999718e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999762e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999831e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999848e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999868e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999876e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999898e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999922e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999927e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999961e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999965e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999965e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999972e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999988e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999989e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999990e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999991e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999993e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999995e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999995e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999996e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999996e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999997e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999997e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999998e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999998e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999998e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999998e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999999e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999999e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999999e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |